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ABSTRACT 
Cancer patients frequently generate cellular immune response to Her-2, a 
protein implicated in promoting tumor growth. While 40% of cancers express HLA 
class II, the ability of class It tumor cells to process endogenous Her-2 and present 
immunogenic peptides for CD4+ T cell recognition is unknown. We addressed this 
question using a CD4+ T cell clone (TCL-6Dn) restricted to Her-2 peptide 883-899 
(p883) presented by HLA-DRPl *0401. We measured the proliferation and cytokine 
response of TCL-6Dn to p883-loaded and Her-2+ tumor cells. Our results showed that 
TCL-6Dn proliferated strongly to p883-loaded DCs, yet TCL-6Dn lysed tumor cells 
in a p883-specific manner. Cytokine production analysis showed that TCL-6Dn 
recognized p883 and produced IFN-y, GM-CSF, TNF-a and IL-4. Tumor cell lysis 
was mediated by a soluble factor produced by TCL-6Dn, but cell contact increased 
lysis. Furthermore, we provide evidence that p883 is a naturally processed HLA class 
II epitope presented by cancer cells. 
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CHAPTER 1. INTRODUCTION 
The immune system responds to tumor cells as tumor antigens are shed from 
the cell surface, picked up and processed by professional antigen presenting cells 
(APCs). APCs degrade the protein into peptides and present them in the context of 
HLA class I and HLA class II molecules for recognition by CDS+ and CD4+ T cells, 
respectively. 
Cancer patients generate cellular immune responses to tumor antigens, but 
often the response is insufficient to eliminate tumors completely (Coulie et al., 1992, 
Disis et al., 2000, Rentzsch et al., 2003). These findings have led to various peptide 
and protein-based immunotherapies. However, a major limitation to peptide-based 
immunotherapy is that peptide-specific T cells may not recognize naturally processed 
tumor antigens (Zaks & Rosenberg, 1998). 
The anti-tumor immune response could be enhanced if CD4+ T cells directly 
recognized tumor cells, presenting tumor-derived antigens in the context of class II 
molecules. Although the intracellular events required for antigen processing and 
presentation are well described for professional APCs, little is known about these 
mechanisms in tumor cells. It is known that, approximately 40% of cancers up-
regulate HLA-DR and other class II molecules, such as HLA-DM, -DO, Ii and CIITA 
(Concha et al., 1995, Oldford et al., 2004, Saito et al., 1997, Ishigami et al., 2001, 
Khalil et al., 2002, Rossi et al., 2002). Potentially, tumor cells themselves may act as 
antigen presenting cells capable of processing and presenting tumor peptides to 
activate CD4+ T cells. Her-2, a tumor-associated antigen, is over-expressed in 25-35% 
of various carcinomas (Afify et al., 1999, Menard et al., 2000, Brabender et al., 2001, 
Parton et al., 2004), but the ability of tumor cells to process and present endogenous 
Her-2 for CD4+ T cell recognition is not well described. The objective of this study 
was to determine if Her-2+ and HLA class II+ tumor cells were able to process and 
present Her-2-derived epitopes for CD4+ T cell recognition. To address this question 
a CD4+ T cell clone, TCL-6D, specific for Her-2 peptide 883-899 (p883) and 
described by Kobayashi et al. (2000) was used. Activation of the T cell clone was 
measured by cytokine production and proliferation. Therefore, this chapter reviews 
pertinent literature on HLA class II and cancer, the role of CD4+ T cells in anti-tumor 
immunity, the role of Her-2 in cancer and the Her-2-specific cellular immune 
response. 
1.1. HLA Structure and Function 
Human leukocyte antigens (HLA), also referred to as major histocompatibility 
complex antigens (MHC), are encoded by genes in three distinct regions of 
chromosome 6 corresponding to HLA class I, class II and class III molecules 
(Reviewed in Rees & Mian, 1999, McFarland & Beeson, 2002). The three HLA 
regions constitute a single HLA haplotype. An individual possesses two co-
dominantly expressed haplotypes (one maternal and one paternal). 
HLA class I antigens (HLA-A, -Band -C) are highly polymorphic, expressed 
on all cells and present endogenously derived antigens to CDS+ T cells. Class I 
molecules are composed of a~, a2, a3 chains and a p2_microglobulin domains, with the 
al and a2 folding into a peptide binding cleft that is closed on both ends and 
restricted to binding 8-10 amino acid peptides (Bjorkman et al., 1987). The peptide 
binding groove of class I molecules contains pockets at the termini of the groove that 
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secure the peptide's carboxyl and amino groups in a manner independent of the 
peptide sequence (Bouvier & Wiley, 1994). 
HLA class II molecules present peptides generated from exogenous antigens 
to CD4+ T cells. Analogous to class I, class II molecules (HLA-DR, -DP and -DQ) are 
polymorphic. However, class II molecules are primarily expressed on professional 
APCs, such as B cells, macrophages and dendritic cells (DCs). Class II molecules are 
composed of a~ heterodimers and the a 1and ~1 domains form a peptide binding cleft 
that is open on both ends, allowing longer peptides (13-25 amino acids) to be loaded 
in the groove (Rudensky et al., 1991, Chicz et al., 1992). X-ray crystallography of 
class II molecules revealed that several peptide side chains bind to the polymorphic 
pockets (PI, P4, P6, and P9) that line the peptide-binding groove (Smith et al., 1998, 
Lee et al., 2001, Fremont et al., 2002, Liu et al., 2002). The class II and peptide 
complex is stabilized by hydrogen bonds formed between the conserved residues on 
the MHC and the peptide back-bone carboxyl and amino groups (Reviewed in 
McFarland & Beeson, 2002). 
1.2. HLA Class II and Cancer 
1.2.1. HLA Class II Expression 
Although class II molecules are normally expressed on APCs, class II 
expression on normal epithelium is variable. Studies have shown that normal breast, 
cervical and intestinal tissues do not express class II (Bartek et al., 1987, Fais et al., 
1991, Hilders et al., 1994, Concha et al., 1995, Haraldsen et al., 1998, Levig et al., 
2002). Other studies reported low levels of class II on normal intestinal epithelium 
with enhanced expression in inflammatory conditions, suggesting inflammatory 
3 
cytokines up-regulate class II expression (Hershberg et al., 1997, Rorie et al., 1998). 
Indeed, cytokines, such as IFN-y, IFN-a, and IL-2 up-regulate class II expression on 
human colon epithelium and melanoma cells, while TNF-a enhances IFN-y-induced 
class II expression on human colon epithelium (Nistico et al., 1990, Watanabe and 
Jacob, 1991, Rorie et al., 1998). 
Class II molecules have also been detected on various types of cancers (Bartek 
et al., 1987, Hilders et al., 1994, Cabrera et al., 1992, Concha et al., 1995, Maiorana et 
al, 1995, Gastl et al., 1996, Tamiolakis et al., 2003). For example, Concha et al. 
(1995) showed that 34% of breast cancers expressed HLA-DR, whereas DQ and DP 
were expressed on 18% and 12%, respectively. More recently, Oldford et al. (2004) 
studied class II protein expression on breast carcinoma and reported that 40% of 
tumors expressed HLA-DR. Other cancers, such as 80% of cervical, 60% of ovarian 
and 50% of colon, express HLA-DR (Hilders et al., 1994, Tamiolakis et al., 2003, 
Levig et al., 2002). 
The biological significance of HLA-DR on cancer cells is controversial. 
Studies have shown HLA-DR expression on ovarian, gastric and colon cancer is 
associated with a good prognosis (Ma et al., 1994, Levig et al., 2002, Tamiolakis et 
al., 2003). In contrast, Maiorana et al. (1995) showed no such correlation in breast 
cancer patients. The high degree of polymorphisim of HLA alleles leads to variation 
in the antigen recognition site. Consequently, specific HLA alleles may lead to 
resistance or susceptibility to cancer. The association between HLA-DR allelic 
expression on cancer cells in general and prognosis has been controversial. Carriage 
ofHLA-DRP1*0401, *11, *1501 and *1601 alleles is associated with an increased 
risk of cancer development (Odunsi et al., 1996, Beskow et al., 2001, Lee et al., 2002, 
4 
Madeleine et al., 2002). Others have shown that HLA-DR~l*0301, *13, *11 and 
*0101 alleles may be protective alleles in cancer development (Odunsi et al., 1996, 
Chaudhuri et al., 2000, Madeleine et al., 2002). However, Gourley et al. (2003) found 
no association between HLA-DR allelic carriage and prognostic outcome. 
1.3. Role ofT Cells in Anti-Tumor Immunity 
Substantial experimental evidence suggests that an anti-tumor immune 
response occurs when tumor antigens are shed from the cell surface or released from 
dying/degrading tumor cells (Chiodoni et al., 1999, Hoffmann et al., 2000). As 
illustrated in Figure 1.1, tumor antigens are captured by professional APCs, such as 
DCs, generating peptides that are loaded onto class I or class II molecules. These DCs 
traffic to the draining lymph node where they mature and interact with CD8+ T cells 
and CD4+ T cells (Pieters, 1997). 
Much attention has been given to CD8+ T cells in the anti-tumor immune 
response because most tumors are HLA class I positive and a large number of HLA 
class !-restricted epitopes derived from tumor antigens have been identified (Peoples 
et al., 1995, Brossart et al., 1999, Nagorsen et al., 2000). Furthermore, cytotoxic CD8+ 
T cells lyse tumor cells directly and eradicate large tumor masses in-vivo (Townsend 
& Allison, 1993, Seki et al., 2002). 
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Figure 1.1. The role of CD4+ T cells in mediating anti-tumor immunity. Dendritic cells may capture shed tumor antigens and 
present antigenic peptides to CD4+ and CDS+ T cells. Activated effector cells may then destroy the tumor cell. Tumor cells also 
directly present tumor peptides to activate CD4+ and/or CDS+ T cells. CD4+ T cells play a central role in regulating the immune 
response through the following mechanisms; (a) help CDS+ T cells differentiate into cytolytic anti-tumor CTLs (b) provide help forB 
cell activation (c) inhibit tumor cell growth directly in a manner similar to CTL killing or generate cytokines which may inhibit 
tumor growth indirectly (d) recruit tumoricidal effector cells (i.e. macrophages and eosinophils). Adapted from Wang, 2001, Pardoll 
& Topalian, 199S and Knutson & Disis, 2005. 
1.3.1. Role of CD4+ T cells in Anti-Tumor Immunity 
The discovery ofHLA class II-restricted epitopes derived from tumor antigens 
led to re-evaluation of the role CD4+ T cells play in tumor eradication (Reviewed in 
Pardoll & Topalian, 199S, Toes et al., 1999, Wang, 2001). Naive CD4+ T (ThO) cells 
recognize tumor peptides presented by class II molecules on DCs. Depending on the 
DCs activation state, microenvironment and cytokines present, naive ThO cells can 
differentiate into Th1 or Th2 effector CD4+ T cell subtypes (Reviewed in Rajnavolgyi 
& Lanyi, 2003). Typically Th1 cells produce IL-2, TNF-a and IFN-y, whereas Th2 
cells produce IL-4, IL-5, IL-10 and IL-13 (Bucy et al., 1994, Openshaw et al., 1995, 
Abbas et al., 1996). Although Th1 and Th2 cells produce different cytokines, both 
subsets play an essential role in the anti-tumor immune response. Th1 cells provide 
help to prime the CDS+ T cell response, while Th2 cells activate B cells to become 
antibody-secreting plasma cells (Reviewed in Wang, 2001). 
1.3.1.1. Maintaining the CDS+ T Cell Response 
CDS+ T cells are believed to be the predominant anti-tumor effector cells, 
while CD4+ T cells provide help to DCs for the activation of CDS+ T cells. Indeed, 
researchers have shown that CD4+ T cells are essential in the induction of a tumor-
specific CDS+ T cell response (Hung et al., 199S, Baxevanis et al., 2000, Reilly et al., 
2001). CD4+ T cell help is partly mediated by the interaction ofCD40 on the DC with 
CD40L on the CD4+ T cell. This interaction leads to the expression of co-stimulatory 
molecules, such as CDSO and CDS6, enabling the DC to co-stimulate the CDS+ T cell 
directly (Schoenberger et al., 199S). In addition, CD4+ T cells generate IL-2 to 
maintain the CDS+ T cell response (Rosenberg et al., 199S). 
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1.3.1.2. Activation and Recruitment of Effector Cells 
Recent evidence suggests tumor specific CD4+ T cells travel to the tumor site 
where they secrete cytokines, such as TNF-a, IFN-y and IL-2 (Kagamu & Shu 1998, 
Wong et al., 1998). Through the release of IFN-y, IL-2, IL-4 and GM-CSF, CD4+ T 
cells recruit and activate other effector cells at the tumor site (Tepper et al., 1992). 
Indeed, mice challenged with B 16 tumor cells had high levels of tumor infiltrating 
macrophages and eosinophils, while these cells were completely absent in the tumor 
site of CD4 -1- mice (Hung et al., 1998). 
Th2 cells enhance the anti-tumor immune response by activating antigen-
specific B cells to become plasma cells, which generate tumor-specific antibodies that 
recognize antigens on cancer cells (Imahayashi et al., 2000, Yasuda et al., 2002, Ichiki 
et al., 2004). Immunization studies using B cell epitopes derived from Her-2 tumor 
antigen generated a peptide-specific antibody response that inhibited tumor growth in-
vitro by complement dependent- and antibody dependent-cell lysis (Jasinska et al., 
2003). 
1.3.1.3. Direct Elimination by CD4+ T cells 
The mechanism by which CD4+ T cells eliminate tumor cells, in the absence 
of CDS+ T cells, is unclear. Studies have shown that CD4+ T cells kill tumor cells in 
an HLA-restricted manner (Xiang et al., 1998, Zennadi et al., 2001). For example, 
Zenaddi et al. (2001) demonstrated that Th2 cells lyse autologous melanoma cells in 
an HLA-DR-restricted manner via the Fas/FasL pathway. Meanwhile, Thomas et al. 
(1998a) illustrated that CD4+ T cells kill melanoma cells in an HLA-DR-restricted 
manner mediated by perforin and granzymes as tumor cell lysis was Ca2+ -dependent 
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in 3 of the 4 CD4+ T cell clones. However, one of the CD4+ T cell clones lysed 
autologous melanoma cells by a TNF -a-dependent mechanism. 
CD4+ T cells also kill tumor cells in a cytokine-mediated manner not requiring 
cell contact (Mumberg et al., 1999, Brady et al., 2000, Hess et al., 2003). In fact, 
CD4+ T cells kill class II positive and negative tumor cells in-vitro and in-vivo by the 
indirect effects of IFN-y (Mumberg et al., 1999, Brady et al., 2000). Tumor-
infiltrating CD4+ T cells also lyse autologous lung carcinoma cells via 
perforin/granzyme and AP02L!fRAIL-mediated pathways (Dorothee et al., 2002). 
1.4. Human Tumor Antigens 
Tumor antigens can be divided into two main categories known as tumor-
specific and tumor-associated antigens (Reviewed in Platsoucas et al., 2003). Tumor-
specific antigens are only expressed on tumor cells. These may be newly-expressed 
antigens or antigens that contain mutations compared to their normal counterparts, 
such as p-catenin, cyclin-dependent kinase 4 and Caspase-8 (Wolfel et al., 1995, 
Robbins & Kawakami, 1996, Mandruzzato et al., 1997). Conversely, tumor-
associated antigens are expressed on both normal cells and tumor cells, but are usually 
over-expressed on tumor cells. Various tumor-associated antigens have been 
discovered, including MAGE-l, MAGE-2, MAGE-3, BAGE, GAGE, NY-ESO, 
Mart-1, gplOO, tyrosinase, Her-2, mutated p53 and MUC-1 (Jerome et al., 1991, 
Traversari et al., 1992, Brichard et al., 1993, Coulie et al., 1993, Nagai et al., 1993, 
Yanuck et al., 1993, Bakker et al., 1994, Kawakami et al., 1994, Boel et al., 1995, 
Van den Eynde et al., 1995, Chen et al., 1997). 
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1.5. Her-2 and Cancer 
A prototype tumor-associated antigen for immunotherapy is Her-2 (also 
known as Her2/neu or erbB2), an 185kDa transmembrane protein expressed at low 
levels on normal tissues and over-expressed on a variety of cancers. 
1.5.1. Biological Role of Her-2 
Her-2 belongs to the human epidermal growth factor receptor (Her) family, 
consisting of four receptors known as Her-1, Her-2, Her-3 and Her-4 (Coussens et al., 
1985). As illustrated in Figure 1.2, Her-2 receptors are transmembrane proteins with a 
large extracellular domain (632 amino acids), a short transmembrane domain (22 
amino acids) and a cytoplasmic domain (580 amino acids) (Choudhury & Kiessling, 
2004). Her-2 receptors are also expressed on a variety of human tissues and have 
tyrosine kinase activity within an intracellular domain, yet the Her-2 ligand has not 
been identified (Cachet et al., 1984, Penuel et al., 2001). 
Although Her receptors usually exist as monomers, upon ligand binding, 
heterodimers and homodimers of the Her receptors form, resulting in phosphorylation 
of the intracellular tyrosine kinase (see Figure 1.3.). The combination of receptors 
formed and the ligand with which the dimer interacts determines the signal pathway 
stimulated. Potentially ten different dimers can form between the various Her 
proteins. However, a hierarchy of inter-receptor relationships exists that favours Her-2 
as a dimer partner (Reviewed in Rubin & Y arden, 2001, Y arden, 2001 ). 
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1.5.2. Role of Her-2 in Cancer 
There is no published evidence of mutations in the Her-2 protein leading to 
cancer. Meanwhile, Her-2 is up-regulated in a broad spectrum of human cancers, 
including 25-30% of breast, 25% of ovarian, 35-45% of pancreatic and 35% of lung 
cancers (Lei et al., 1995, Afify et al., 1999, Menard et al., 2000, Brabender et al., 
2001, Parton et al., 2004). 
In normal cells, activation of Her receptors is highly controlled, resulting in 
activation of a signalling pathway that promotes normal cell growth, differentiation 
and development through the mitogen-activated protein kinase pathway (MAPK) 
(Cousssens et al., 1985, Lee et al., 1995, Threadgill et al., 1995). Normal expression 
of Her-2 on cells results in few Her-2 combinations and provides weak but essential 
signals for cell growth (Lin et al., 2000). However, cells that over-express Her-2 show 
uncontrolled cell growth (Neve et al., 2000, Goebel et al., 2002). 
Up-regulation of Her-2 contributes to increased tumor cell growth by various 
mechanisms. The anti-apoptotic effect ofHer-2 has been attributed to activation of the 
phosphatidylinositol 3-kinase (PI3K) and MAPK pathways, which increase the 
expression of anti-apoptotic proteins, such as BCL and C-FLIP (Daly et al., 1999, 
Neve et al., 2000, Bhat-Nakshatri et al., 2002). Up-regulation of Her-2 is associated 
with increased tumor invasiveness as Her-2 enhances the secretion of matrix 
metalloproteases, which accelerate the breakdown of normal connective tissue and 
boost tumor metastasis (loachim et al., 1998, Pellikainen et al., 2004). Her-2 is 
believed to signal via the PBK pathway, inducing release of phosphoinositides, which 
contribute to actin re-organization and enhance tumor migration (Feldner & Brandt, 
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2002). Her-2 is also associated with up-regulation of vascular endothelial growth 
factor (VEGF), increasing tumor vascularity (Konecny et al., 2004). 
Studies have examined the relationship between Her-2 expression and clinical 
outcome, illustrating that over-expression of Her-2 is associated with disease 
progression, metastatic phenotype, poor clinical outcome and higher resistance to 
chemotherapy (Press et al., 1993, Tsai et al., 1996, Menard et al., 2001, Masood & 
Bui, 2002). Thus, the direct contribution of Her-2 in the development and metastasis 
of cancer has made this molecule an attractive target for anti-cancer therapy. 
1.5.3. Cellular Immune Response to Her-2 
Although the immune system is unable to protect against the growth ofHer-2+ 
tumors, interestingly these patients generate antibody and T cell responses against 
Her-2 (Rentzsch et al., 2003, Sotiropoulou et al., 2003). Her-2 vaccination studies 
have shown that this anti-tumor response is enhanced in patients with ovarian, gastric, 
breast and lung cancers (Fisk et al., 1997, Tuttle et al., 1998, Disis et al., 2002, Kono 
et al., 2002). Thus, Her-2 may be a promising target for T cell-based 
immunotherapies. 
1.5.3.1. Her-2 Specific CD4+ T Cell Response 
Incorporation of both class I and class 11-restricted epitopes in vaccines results 
in a more efficient and longer lasting anti-tumor immune response (Ossendorp et al., 
1998, Knutson et al., 2001 ). Consequently, researchers have attempted to identify 
class II epitopes from the Her-2 protein. One such class 11-restricted peptide (777-
798) was presented by HLA-DR4 and recognized by CD4+ T cells in breast cancer 
patients (Tuttle et al., 1998). Similarly, DCs retrovirally transduced to express Her-2 
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protein presented Her-2 peptides in the context of HLA-DR and generated an 
autologous CD4+ T cell response in Her-2 positive breast cancer patients (zum 
Buschenfelde et al., 2001 ). 
Additional studies have shown that Her-2 contains immunogenic epitopes that 
bind promiscuously to various lll.A-DR molecules. In particular, Her-2 peptide 776-
788 was presented by HLA-DR~5*0101, HLA-DR~1 *0701 and HLA-DR~1 *0405, 
activating CD4+ T cells (Sotiriadou et al., 2001). Similarly, Kobayashi et al. (2000) 
identified Her-2 peptides capable of eliciting a CD4+ T cell proliferative response. 
One ofthese peptides (883-899) was promiscuously presented in the context ofHLA-
DR1, DR4, DR52 and DR53. Consequently, Her-2 peptides 776-788 and 883-899 
bind to various class II molecules and may offer broad population coverage for 
immunotherapy. 
1.6. HLA Class II Antigen Processing in Tumor Cells 
1.6.1. HLA Class II Antigen Processing Pathway 
Loading of peptides, generated from exogenous proteins, onto class II 
molecules is a multi-step process (see Figure 1.4.) and mainly occurs in professional 
APCs. Initially, HLA class II a. and~ subunits in the endoplasmic reticulum form an 
association with the invariant chain (Ii), which inhibits peptide binding by the class II 
molecules (Roche & Creswell., 1990). Trimerization of the Ii facilitates binding of 
three a.~ class II molecules and forms a nonomeric complex ( a.~Ii)3 that is directed 
through the endoplasmic reticulum to the Golgi and into the endosomes (Layet et al., 
1991, Bikoffetal., 1993, Reviewed in Wang, 2001, Watts, 2004). 
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Removal of the Ii from class II molecules is achieved in the late endocytic 
compartment called the MIIC (MHC class II compartment). Aspartyl and cysteinal 
proteases in the MIIC degrade the Ii leaving a fragment known as CLIP (class II-
associated invariant chain protein) in the peptide binding groove (Busch et al., 2000, 
Bania et al., 2003). HLA-DM, in association with HLA-00, facilitates the removal of 
CLIP and stabilizes the empty class II molecule (van Ham et al., 2000, Hsieh et al., 
2002). Thereafter, HLA-DM and HLA-DO assist in editing the selection of tightly 
binding peptides derived from proteins that are also degraded in the endocytic 
pathway (Reviewed in Kropshofer et al., 1999). Peptide-class II complexes are 
transported to the cell surface where they are recognized by CD4+ T cells. 
1.6.2. Binding of Peptides Derived From Endogenous Proteins onto HLA Class II 
Molecules 
HLA class I molecules generally present peptides generated from endogenous 
(cytosolic) proteins, whereas class II molecules present peptides from exogenous 
proteins (Figure 1.4). However, cytosolic antigen-derived peptides have been eluted 
from class II molecules (Reviewed in Zhou & Blum, 2004). According to Chicz et al 
(1993), over 85% of the peptides eluted from class II molecules on human B cells 
were derived from endogenous proteins. Several pathways have been implicated in 
the presentation of cytosolic protein-derived peptides onto HLA class II molecules. 
For instance, peptides derived from cytosolic proteins, such as GAD (glutamic acid 
decarboxylase) and influenza viral proteins require cytoplasmic processing by the 
proteasome and TAP (Lich et al, 2000, Tewari et al., 2005). 
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Alternatively, autophagy has been implicated in the presentation of cytosolic 
antigen-derived peptides by class II molecules. This process involves the 
sequestration of cytosolic proteins in autophagolysosomes that fuse with the lysosome 
where antigens are degraded and loaded onto class II molecules. Cytosolic proteins 
acquired through autophagy, such as the Epstein bar virus nuclear antigen and the 
neomycin phosphotransferase II (NeoR) antigen, are processed by acidic proteases in 
the lysosomal compartments of the class II processing pathway (Nimmetjahn et al., 
2003, Paludan et al., 2005). In contrast, Dorfel et al., 2005 have shown that 
proteasomal and endosomal compartments are required for the presentation of class II 
epitopes from cytosolic proteins in DCs. 
1.6.3. Expression of HLA Class II Antigen Processing Molecules in Tumor 
Cells 
Class II antigen processing molecules (li, HLA-DM and HLA-DO) are mainly 
expressed in professional APCs and can be up-regulated by cytokines, such as IFN-y, 
in other cell types (Chang & Flavell, 1995, Boss & Jensen, 2003). Although the 
expression of class II processing molecules in tumor cells is not well resolved, studies 
using immunocytochemistry have shown that 15% of colorectal, 38% of gastric and 
54% of breast tumors express invariant chain (lshigami et al., 2001, Rossi et al., 2002, 
Oldford et al., 2004). Until recently, HLA DO expression was only documented in 
lymphoid cells (Alfonso & Karlsson, 2000). However, recent studies demonstrated 
that myeloid leukemia cells express HLA class II/CLIP complexes (Khalil et al., 
2002, Chamuleau et al., 2004). Thus, tumor cells may be capable of processing tumor 
antigens and presenting peptides. 
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1.6.4. Role of liLA Class II Antigen Processing Molecules in Tumor Cells 
Transfection of the class II transactivator (CIITA) into murine mammary 
adenocarcinoma has led to expression of class II molecules and anti-tumor immunity 
(Meazza et al., 2003). Activation of the CIITA gene upreguates HLA class II and 
HLA class II-associated accessory molecules, such as HLA-DM and Ii (Chang & 
Flavell, 1997). However, expression of class II and class II-accessory molecules on 
tumor cells does not necessarily confer antigen processing capabilities. Given that the 
role of the Ii chain is to protect the peptide binding groove of class II molecules, one 
would expect that tumor cells expressing HLA-class II molecules in the absence of 
class II-associated molecules would be better suited to endogenously process tumor 
antigens. Indeed, mouse-transfectant studies demonstrated that tumor cells expressing 
class II without co-expression of the Ii or Ii and DM are immunogenic and present 
endogenous antigens, while class II positive tumor cells co-expressing the Ii or Ii and 
DM are not immunogenic (Armstrong et al., 1997). Meanwhile, suppression of the Ii 
chain expression in class 11-positive murine tumors can result in increased tumor 
clearance (Qiu et al., 1999). 
1.6.5. Antigen Presenting Capacity of Tumor Cells 
Tumor cells generally lack the co-stimulatory molecules, CD80 and CD86, 
necessary to activate naive T cells (Staveley-O'Carroll et al., 1998, reviewed in 
Schwartz et al., 2002). However, manipulation of tumor cells to express co-
stimulatory molecules can confer antigen presenting capabilities to the tumor cell 
(Reviewed in Allison et al., 1995, Hurwitz et al., 2000). Recent evidence suggests 
that tumor specific CD4+ T cells activated by professional APCs travel to the tumor 
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site where they secrete cytokines, such as TNF-a, IFN-y and IL-2 (Kagamu and Shu 
1998, Wong et al., 1998). Production of IFN-y can up-regulate HLA-class II 
molecules on tumor cells, possibly resulting in tumor antigen processing, presentation 
and recognition by tumor infiltrating effector CD4+ cells. 
1. 7. Hypothesis 
Previously, Kobayashi et al. (2000) showed that TCL-6D recognized the Her2 
peptide p883 presented by HLA-DR~1 *0401 molecules. In particular, TCL-6D 
proliferated strongly in response to p883-pulsed DR~ 1 *040 1 + DCs, PBMCs and L 
cells. However, in this study, Kobayashi et al. (2000) did not assess the cytokine 
profile generated by activated TCL-60, but showed that another p883-specific CD4+ 
T cell clone, TCL-7C, produced GM-CSF in response to p883-pulsed DCs. 
Consequently, an important aim was to determine the cytokines produced by TCL-6D 
upon recognition of p883-pulsed APCs. 
TCL-6D recognized p883 presented by DR~1 *0401+ L cells, which lack co-
stimulatory molecules CD80 and CD86 (Kobayashi et al., 2000). Therefore, we 
hypothesized that HLA-DR+ tumor cells, also lacking co-stimulatory molecules, 
might present p883 to activate TCL-60. Generally, tumor cells do not express class II 
molecules, but studies have shown that class II molecules are up-regulated by various 
cytokines (Nistico et al., 1990, Watanabe & Jacob, 1991, Rorie et al., 1998). Thus, we 
predicted that HLA-DR+ tumors would present exogenous p883 to activate TCL-60. 
Although expression of class II antigen processing molecules on tumor cells is 
not well resolved, tumor cells can up-regulate HLA class II processing molecules 
(lshigami et al., 2001, Khalil et al., 2002, Rossi et al., 2002, Chamuleau et al., 2004, 
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Oldford et al., 2004). Therefore, we asked whether Her-2+ and class It tumor cells 
were able to process endogenous Her-2 protein, presenting p883 to activate TCL-6D. 
Studies have shown that HLA-DR+ tumor cells are capable of presenting tumor 
peptides, eliciting a CD4+ T cell tumor-specific response (Reviewed in Ostrand-
Rosenberg, 1994, Fisk et al., 1995, Armstrong et al., 1997, Armstrong et al., 1998a, 
Armstrong et al., 1998b). In addition, Her-2 epitopes 776-788 and 884-899 are 
naturally processed epitopes presented on tumor cells that are recognized by CD4+ T 
cell clones (Sotiriadou et al., 2001, Perez et al., 2002). Consequently, we predicted 
that tumor cells expressing HLA class II antigen processing molecules and Her-2 
protein would endogenously process and present Her-2 peptides, activating the Her-2 
p883-specific CD4+ T cell clone. 
1.8. Objectives 
i. To determine the cytokines produced by TCL-60 upon recognition of p883-
pulsed APCs. 
ii. To investigate the ability of TCL-6D to respond to exogenous p883-pulsed 
HLA-DR+ tumor cells. 
iii. To examine the ability of HLA class Ir and Her-2+ tumor cells to process 
endogenous Her-2 and present the 883-899 epitope to activate TCL-6D. 
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CHAPTER2.METHODOLOGY 
2.1. Cell Culture 
2.1.1. Culture and Maintenance of Cell Lines 
Tumor cell lines and mouse fibroblasts cell lines (L cells) (Table 2.1) were 
grown as adherent cell cultures in 25 cm2 tissue culture-treated flasks (Coming 
Incorporated, Coming, NY, USA). EBV-transformed B cell lines (BCLs), T cell line, 
Jurkat, and NK cell line (C10MJ) were grown as suspension cultures. C10MJ was 
grown in RPMI 1640 (GibcoBRL, Grand Island, NY, USA) while other cell lines 
were cultured in Iscove's Modified Dulbeco's Medium (IMDM). Both RPMI and 
IMDM media were enriched with 10% heat-inactivated fetal calf serum (FCS), 2 mM 
L-glutamine and antibiotics penicillin (1 00 U/ml) and streptomycin (1 00 Jlg/ml) and 
antimycotic amphotericin B (0.25 J.tg/ml; all obtained from GibcoBRL). 
Adherent cells were harvested and sub-cultured when cell growth was 90-
100% confluent. Medium was aspirated from the culture flask and adherent cells were 
detached using 5 ml of 0.25% trypsin diluted in sterile phosphate buffered saline 
solution (PBS) for 3-5 min at 37°C. Five millilitres of enriched IMDM was added to 
the flask, to inactivate the trypsin. Cells were transferred to sterile 15 ml 
polypropylene tubes, centrifuged at 300 g for 7 min and washed in 5 ml of enriched 
IMDM. Cell pellets were resuspended in 5 ml of enriched IMDM and 3 x 105 cells 
were re-seeded into culture flasks containing 7 ml of enriched IMDM. 
BCLs (see Table 2.2) and ClOMJ were maintained at 3 x 105 cells/ml and 6 x 
105 cells/ml, respectively and Jurkat was maintained at 2 x 105 cells/mi. Cells were 
cultured at 3rc, in a 6.5% C02 humid chamber. 
22 
N 
w 
Table 2.1. Descnpt10n of tumor cell lines and L cell lines used in this study 
Tumor Cell Line Source 
HT29 R. Hershberg 
HT29-*0401 R. Hershberg 
T47D J. Blum 
T47D- *0401 J. Blum 
MDA MB 435 J. Blum 
MDA MB 435- J. Blum 
*0401 
L243.6 R. Karr 
L164.11 R. Karr 
Description 
Colon Carcinoma 
Colon Carcinoma 
Breast Carcinoma 
Breast Carcinoma 
Transfected 
HLA-DR 
None 
DRP1*0401 
None 
DRPI *0401 
Breast Carcinoma** None 
Breast Carcinoma** DRPI *0401 
Mouse Fibrobalst DRPI *0401 
Mouse Fibroblast DRP 1 *040 1 
Amencan Type Culture CollectiOn (Manassas, VA) 
Constitutive 
HLA-DR 
None 
None 
DRPI *0102 
DRPI *0102 
DRP1*1320 
DRP1*1320 
None 
None 
IFN-y induced 
HLA-DR Type 
DRPI *0402, *0701, DRP4 
DRPI *0402, *0701, DRP4 
DRPI *0102 
DRP1*0102 
DRPI *0404, DRPI * 13, DRp3, 
DRP4 
DRPI *0405, DRPI *1320, DRp3, 
DRP4 
None 
None 
**Using DNA microarrays, MDA MB 435 was found to express melanoma associated genes (Ross et al., 2000). 
Table 2.2. Human B cell lines used as feeder cells to expand TCL-6Dn or as control 
APCs in this study. 
B Cell Lines IHW** HLA-DR Type 
Identification 
MGAR IHW 9014 DRB1 *1501, DRB5*0101 
YAR IHW9026 DRB1 *0402, DRB4*0101 
JESTHOM IHW9004 DRB1*0101 
SAVC IHW 9034 DRB1 *0401, DRB4*0101 
PLH IHW9047 DRB1 *0702, DRB4*0101 
ffiW9 IHW 9049 DRB1 *0701, DRB4*0101 
MT14B IHW 9098 DRB1 *0404, DRB4*0101 
SWEIG007 IHW 9037 DRB1 *1101, DRB3*0202 
DBB IHW9052 DRB1 *0701, DRB4*0101 
MZ070782 IHW 9002 DRB1*0102 
* * Ninth International Histocompatibility Workshop 
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2.1.2. Expansion and Culture of p883-Specific T Cell Clone 
TCL-6D, a CD4+ T cell clone restricted to Her-2 peptide 883-899 (p883) 
presented in the context ofHLA-DR~1*0401 molecules was a gift from Dr. E. Celis 
(Mayo Clinic, Minnesota, USA). TCL-6D was expanded, now called TCL-6Dn, in 
RPMl 1640 medium supplemented with 10% heat-inactivated FCS, 0.1 mM MEM 
non-essential amino acids, 1 mM sodium pyruvate, 2 mM L-glutamine, 50 Jlg/ml 
gentamicin, 25 J.1M 2-ME and antibiotic/antimycotic containing 100 U/ml penicillin, 
100 Jlg/ml streptomycin and 0.25 Jlg/ml amphotericin B (all obtained from 
GibcoBRL). On day 0 ofthe expansion, 2 x 104 T cells/ml were combined with 30 
ng/ml of anti-CD3 (OKT3), 2 x 105 irradiated (y8000 rads) mixed human BCLs/ml 
and 2.5 x 107 irradiated (y4200 rads) human PBMCs/ml that were collected from 
various healthy donors and pooled. Twenty-five ml ofT cell expansion mixture was 
placed in a 50 ml tissue culture flask and incubated for 18 days. 
On day one, 50 units/ml of recombinant human interleukin-2 (IL-2) was added 
to each flask. On days 5, 8, 11 and 14, 12.5 ml of supernatant was gently removed 
from each flask and replaced with fresh T cell medium supplemented with 50 units/ml 
of rhiL-2 (Hoffmann-LaRoche, Nutley, NJ, USA). On day 18, T cells were counted 
and cultures were centrifuged at 300 g for 7 min. Cell pellets were resuspended at 5 x 
106/ml in freezing solution containing 10% dimethyl sulfoxide (DMSO; Sigma, Saint 
Louis, Missouri, USA) in FCS. Aliquots of T cells were placed in a minus 70°C 
freezer for a minimum of 24 h, prior to being stored in liquid nitrogen. 
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2.2. lnterferon-y Treatment of Tumor Cell Lines 
To up-regulate MHC class II and class II co-chaperone molecules, tumor cells 
were treated with recombinant human interferon gamma (rhiFN-y; BD Pharmingen, 
San Diego, CA, USA). Prior to rhiFN-y treatment, tumor cell lines were sub-cultured 
(as described in Section 2.1.1) and rested overnight at 37°C. On day 0, one culture 
was treated with 500 units/ml rhlFN-y and a second culture was left un-treated in 
order to determine constitutive expression of class II molecules. Cells were incubated 
for 96 h. 
2.3. Isolation of Peripheral Blood Mononuclear Cells 
Peripheral blood mononuclear cells (PBMCs) from healthy donors were 
isolated by density gradient centrifugation. Blood was collected in tubes containing 
anticoagulant acid citrate dextrose solution (BD Biosciences, Rutherford, NJ, USA) 
and centrifuged at 700 g, 18°C for 15 min. The PBMC layer was collected and diluted 
1:2 with 0.9% NaCl solution (Baxter, Toronto, ON, Canada). Ten ml of diluted blood 
was layered over 5 ml of lymphoprep (Nycomed, Oslo, Norway) in a 15 ml 
polypropylene tube and centrifuged at 550 g, 18°C for 35 min. The PBMC layer was 
sterilely collected, washed twice in Hanks balanced salt solution (HBSS; GibcoBRL) 
and centrifuged at 400 g, l8°C for 10 min. This was followed by two washes in 
enriched IMDM for 7 min at 400 g, 18°C and a final 5 min wash at 150 g to remove 
platelets. Cell pellets were resuspended in 5 ml of enriched IMDM. One-hundred 
microliters of cell suspension was removed, diluted 1:2 with 3% acetic acid to lyse 
any residual erythrocytes and counted, using a hemocytometer counting chamber 
(Fisher Scientific, Nepean, ON, Canada). 
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2.4. In Vitro Generation of Dendritic Cells 
DCs were isolated from the adherent fraction of freshly isolated PBMCs 
obtained from healthy volunteers with the Memorial University's Human 
Investigation Committee's (HIC) approval. PBMCs were isolated as described above 
and were resuspended at 2 x 106 /ml in enriched IMDM. Thereafter, 2 ml of DC 
culture was dispensed into each well of a six-well plate (Fisher Scientific). Plates 
were incubated in a 37°C, 6.5% C02 humidified chamber for 2 h, after which, non-
adherent cells were removed by aspirating the medium and washing each well four 
times with 2 ml ofHBSS. Remaining adherent cells were cultured in 2 ml of enriched 
IMDM supplemented with 1000 units/ml rhGM-CSF (BD Pharmingen) and 1000 
units/ml rhiL-4 (BD Pharmingen) for 7 days. On days two and four, 2 ml of enriched 
IMDM supplemented with 1000 units/ml rhGM-CSF and 1000 units/ml rhiL-4 was 
added to each well. 
TNF-a induces DCs maturation and up-regulation of CD80, CD86 and CD83 
(Tang et al., 2005). To induce maturation of DCs, on day 6 an additional 4 ml of 
enriched IMDM, containing 100 ng ofrhTNF-a (BD Pharmingen) was added to half 
of the wells. Remaining wells received enriched IMDM without TNF-a, causing DCs 
to retain the immature phenotype. On day 7, mature and immature DCs were collected 
in 50 ml polypropylene tubes, on ice, and centrifuged at 300 g for 7 mins at 4°C. 
Pellets were resuspended in enriched IMDM, counted and used as APCs or 
phenotyped by flow cytofluorometry. 
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2.5. Flow Cytofluorometry 
2.5.1. Primary Antibodies 
A description of the mouse monoclonal antibodies (mAbs) used to detect cell 
surface proteins on TCL-6Dn is presented in Table 2.3. Negative isotype controls 
were PE-conjugated mlgGs (DAKO, Carpinteria, CA, USA) and FITC-conjugated 
mlgG 1 (BD Pharmingen). Primary mAbs used to detect intracellular cytokines are 
described in Table 2.4. Negative isotype controls were FITC-conjugated rat IgG2a, rat 
IgG1, mlgG1 (Caltag Laboratories, Hornby, ON, Canada) and un-conjugated mlgG1 
(BD Pharmingen). Primary mAbs used to detect cell surface antigens on in-vitro 
generated DCs are described in Table 2.5. Primary antibodies used to detect HLA-DR 
allelic products (L243, NFLD.D1 and NFLD.D11) were obtained locally. All other 
antibodies were obtained commercially. Negative isotype controls were mlgG 1 and 
mlgG2a and mlgM (BD Pharmingen). 
2.5.2. Secondary Antibodies 
To detect binding of un-conjugated mouse mAbs, PE-conjugated affinipure 
F(ab')2 fragment goat-anti-mouse (GAM) IgG, Fe fragment specific (Jackson 
ImmunoResearch, West Grove, PA) was used. For some experiments, FITC-
conjugated GAM IgG, y and L chain specific (Caltag Laboratories) was used, while 
FITC-conjugated affinipure F(ab')2 fragment donkey anti rat IgG, heavy and light 
chain specific (Jackson ImmunoResearch) was used to detect binding of rat mAbs. 
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Table 2.3. Primary antibodies used to detect expression of cell surface proteins on 
TCL-6Dn by flow cytofluorometry 
Antibody Isotype Directly Concentration Reference/ 
Conjugated Source 
Fluorochrome 
CD2 Mouse PE 5 J.Llltest BD Pharmingen 
Clone S5.2 IgG2a 
CD3 Mouse PE 5 J.Llltest BD Pharmingen 
Clone SK7 lgGl 
CD4 Mouse PE 5 J.Llltest BD Pharmingen 
Clone SK3 IgGl 
CDS Mouse PE 5 J.Llltest BD Pharmingen 
Clone SKI IgGl 
CD16 Mouse PE 16 J.Llltest BD Pharmingen 
Clone B73.1 lgGl 
CD19 Mouse PE 5 J.Llltest BD Pharmingen 
Clone SJ25C 1 IgGl 
CD25 Mouse PE 5 J.Llltest BD Pharmingen 
Clone 2A3 lgGl 
CD38 Mouse PE 5 J.Llltest BD Pharmingen 
Clone HB7 lgGl 
CD45 Mouse PE 5 J.Llltest BD Pharmingen 
Clone 201 IgGl 
CD45RA Mouse FITC 5 J.Llltest BD Pharmingen 
Clone L48 IgGl 
CD45RO Mouse PE 5 J.Llltest BD Pharmingen 
Clone UCHLl IgG2a 
CD 56 Mouse PE 16 J.Llltest BD Pharmingen 
CloneMY31 lgGl 
CD69 Mouse FITC 5 J.Llltest BD Pharmingen 
Clone FN50 lgGl 
CD95 Mouse Un-conjugated 1.0 J.Lg/ml BD Pharmingen 
CloneDX2 lgGl 
CD95L Mouse Un-conjugated 0.2 J.Lg/ml Cal tag 
CloneNOK-1 lgGl Laboratories 
HLA-DR Mouse PE 5 J.Llltest BD Pharmingen 
CloneTU36 lgG2b 
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Table 2.4. Primary antibodies used to detect CD4 expression and intracellular 
cytokines produced by TCL-6Dn measured by flow cytofluorometry 
Antibody Isotype Directly Concentration Reference/ 
Conjugated Source 
Fluorochrome 
IL-2 Rat FITC 8 J.Llltest Caltag Laboratories 
Clone MQ1- IgG2a 
17H12 
IL-4 Rat FITC 8 J.Llltest Caltag Laboratories 
Clone MP4- IgGl 
2502 
IL-10 Rat FITC 8 J.Llltest Caltag Laboratories 
Clone JES3-9D7 lgGl 
IFN-y Mouse FIT.C 8 J.Llltest Caltag Laboratories 
B27 IgGl 
TGF-p Rat Unconjugated 10 J.Lg/ml BD Pharmingen 
Clone A75-2.1 lgG2a 
Mouse Unconjugated 10 J.Lg/ml Neomarkers 
TNF-a lgGl (Union City, CA, 
Clone J1D9 + USA) 
J2DIO 
GM-CSF Rat Unconjugated 5 J.Llltest Caltag Laboratories 
CloneBVD2- lgG2a 
21Cll 
Mouse PE 5 J.Llltest Caltag Laboratories 
CD4 IgG2a 
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Table 2.5. Primary antibodies used to determine the phenotype of in-vitro-generated 
dendritic cells by flow cytofluorometry 
Antibody I so type Specificity Concentration Reference/ 
Source 
CD1a Mouse CD1a 5 J.lg/ml BD Pharmingen 
Clone llll49 IgG1 
CD3 Mouse CD3 5 J.lg/ml BD Pharmingen 
CloneUCHT1 IgG1 
CD14 Mouse CD14 5 J.lg/ml BD Pharmingen 
Clone M5E2 lgG1 
CD19 Mouse CD19 2J.1g/ml Neomarkers 
CloneFMC63 IgG2a 
CD40 Mouse CD40 5 J.lg/ml BD Pharmingen 
Clone 5C3 lgG1 
CD68 Mouse CD68 20 Jlg/ml DAKO 
Clone EMB11 lgG1 
CD80 Mouse CD80 2 Jlg/ml Caltag Laboratories 
Clone DAL-1 lgG1 
CD83 Mouse CD83 5 Jlg/ml BD Pharmingen 
Clone HB15e lgG1 
CD86 Mouse CD86 10 J.lg/ml BD Pharmingen 
Clone BU63 lgG1 
L243 Mouse All HLA- 5 J.lg/ml Lampson & Levy, 
(Supernatant) IgG2a DR 1980 
NFLD.D1 Mouse HLA-DR4 20 J.lg/ml Drover et al., 1994 
(purified) lgG1 
NFLD.Dll Mouse HLA- Neat Drover et al, 1998 
(Supernatant) IgM DRJ31*0401 
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2.5.3. Extracellular Flow cytofluorometry 
2.5.3.1. Utilizing Fluorochrome-Conjugated mAbs 
To detect expression of cell surface antigens, a pre-determined amount (as per 
Tables 2.3 and 2.4) of the fluorochrome-conjugated mAb was added to each 12 x 75 
mm polystyrene tube (Fisher Scientific). Cells were washed once in PBS, once in 
FACS buffer (see appendix 1) and resuspended at 2 x 106/ml in FACS buffer. Fifty J.Ll 
of cell suspension was mixed with the mAb and incubated for 20 min in the dark at 
4°C. Cells were washed twice in 2 ml of ice-cold F ACS buffer, centrifuged at 300 g 
for 5 min at 4°C and cell pellets were re-suspended in 200 J.Ll of 1% paraformaldehyde 
(PF A) (see appendix A). All tubes were protected from light and stored at 4°C for 
approximately 18 h. Ten thousand events were acquired using the F ACScan (Becton-
Dickinson, San Jose, CA). Data was analyzed using Cell Quest pro analysis software 
or WINMIDI 2.8 software. 
2.5.3.2. Utilizing Do-Conjugated mAbs 
Twenty five J.Ll of the un-conjugated mAb, diluted to an optimal concentration 
(Tables 2.3, 2.4 and 2.5) using F ACS buffer was added to each 12 x 75 mm tube. 
Fifty J.Ll of cell suspension was mixed with the mAbs and incubated for 30 min in the 
dark at 4°C. Cells were washed twice in ice-cold F ACS buffer and incubated with 25 
J.Ll of PE-conjugated GAM IgG (Jackson ImmunoResearch), optimally diluted to 25 
J.Lg/ml in FACS buffer, for 30 minutes at 4°C protected from light. Cells were washed 
twice in ice-cold F ACS buffer, fixed and analyzed as described in section 2.5.3.1. 
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2.5.4. Intracellular Flow Cytofluorometry 
Detection of invariant chain (Ii), HLA-DM and Her-2 required fixation and 
permeabilization of the cells. Cells were washed once in ice-cold F ACS buffer, fixed 
in 5 ml of 2% PF A for 15 min at 4°C and washed once in enriched IMDM. Cells were 
permeabilized in 5 ml of 0.2% saponin (Polysciences, Warrington, PA, USA) in PBS 
for 15 min at 4°C and resuspended to 1.5 x 106/ml in permeabilization buffer (1x PBS 
+ 0.5% BSA + 0.2% saponin). Primary mAbs specific for Ii (1 0 llg/ml; clone LN2, 
BD Pharmingen), HLA-DM (5 llg/ml; clone MaP.DM11, BD Pharmingen) and Her-2 
(2.5 llg/ml; clone CBll, NeoMarkers) were diluted in permeabilization buffer. 
Isotype controls included mlgG1, mlgG2a (BD Pharmingen) and mlgG2b (Southern 
Biotech Associates, Birmingham, AL, USA) mAbs. 
Twenty five Ill of mAb was mixed with 50 Ill of cell suspension and incubated 
on ice for 30 min. Cells were washed twice with ice-cold permeabilization buffer and 
incubated with 25 Ill of PE-conjugated GAM-IgG (25 llg/ml) for 30 min on ice 
protected from light. Cells were washed twice in permeabilization buffer, fixed and 
analyzed as described in section 2.5.3.1. 
2.6. Reverse Transcriptase-Polymerase Chain Reaction (RTPCR) 
The presence ofFOXP3 transcripts in TCL-6Dn was assessed by RT-PCR. An 
aliquot of TCL-6Dn was thawed, washed twice in T cell medium and once in PBS. 
Thereafter, RNA was prepared from TCL-6Dn using Trizol reagent (Invitrogen, 
Burlington, ON, Canada) according to the manufacturer's instructions and treated 
with DNAase to remove any contaminating DNA. eDNA was prepared from 1 11g of 
RNA using the first strand eDNA synthesis kit from Pharmacia Biotech (Baie d'Urfe, 
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Quebec, Canada) according to the manufacturer's instructions. Expression ofFOXP3 
was measured using the FOXP3 sense (5' CAG CTG CCC ACA CTG CCC CTA 3') 
and anti-sense (5' CAT TTG CCA G CA GTG GGT AG 3') primers at a fmal 
concentration of 20 pM (Takahata et al., 2004). The housekeeping gene ~-actin was 
included as a positive control to ensure the quality of eDNA in the samples. The ~­
actin sense (5' ATC TGG CAC CAC ACC TIC TAC AAT GAG CTG CG 3') and 
anti-sense (5' CGT CAT ACT CCT GCT TGC TGA TCC ACA TCT GC 3') primers 
(Paterno et al., 1998) were used at a final concentration of 20 pM. 
The PCR amplification was performed in a total volume of 50 Jll and the PCR 
mixture contained 5 fll 1 OX buffer, 1 fll dNTP, 1.5 fll MgC}z, 1 fll eDNA, 1 fll sense 
primer and 1 fll anti-sense primer. The PCR protocol used included 1 min at 94°C, 1 
min at 65°C, 1 min at 72°C repeated for 35 cycles and held at 4°C until the amplified 
products were observed. 
2.7. Antigen-Specific Response ofHer-2 p883-Specific TCL-6Dn 
2.7.1. y-lrradiation ofthe APCs 
Adherent cells were harvested using 0.25% trypsin (see section 2.1.1.) and 
counted, whereas, non-adherent cell lines were removed from culture. Approximately 
1 x 106 of each cell line was transferred to separate 15 ml polypropylene tubes, 
centrifuged at 300 g for 7 min and pellets were resuspended in 15 ml of enriched 
IMDM. 
Irradiation of the APCs was conducted at the J.H. Bliss Murphy Cancer 
Center. L-cells, BCLs, DCs and PBMCs received y4200 rads, whereas tumor cells 
received y20000 rads. Following irradiation, cells were centrifuged at 300 g for 7 min, 
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washed twice in 7 ml of enriched IMDM and cell pellets were resuspended in the 
appropriate medium, depending on the intended use for the irradiated APCs. 
2.7.2. Synthetic Peptides 
The synthetic peptide 883-899 (p883; KVPIKWMALESILRRRF) derived 
from Her-2 was synthesized by Dr. Wang (Banting Institute, Toronto Hospital of Sick 
Kids, Toronto, ON). An irrelevant peptide derived from HIV Gag p24 
SILDIRQGPKEPFRDYVDRF, a kind gift from Dr. M. Grant, was used as a control 
peptide. This HIV peptide was predicted to bind to HLA-DR~1 *0401 molecules using 
a peptide binding prediction algorithm (Venturini et al., 2002). 
2.7.3. Proliferative Response ofTCL-6Dn 
Irradiated APCs were resuspended in T cell medium, containing RPMI 1640 
medium supplemented with 10% heat-inactivated human male AB serum (Atlanta 
Biologicals, Lawrenceville, GA, USA), 2 mM L-glutamine, 1 mM sodium pyruvate, 
50 ug/ml gentamicin, 0.1 mM MEM non-essential amino acids, 100 U penicillin/ml, 
100 J.Lg streptomycin/ml, 0.25 J.Lg amphotericin B/ml. APCs were resuspended at the 
following concentrations; PBMCs 1 x 106/ml, DCs 5 x 104/ml, tumor cells 1 x 105/ml, 
BCLs 1 x 105 /ml and L cells, 1 x 105 /ml. One hundred J.Ll of APCs were plated in 
triplicates in a 96-well u-bottom plate (Fisher Scientific). APCs were pulsed with 1 
J.Lg/ml of peptide or un-pulsed for 2 h. 
During the peptide-pulsing period an aliquot of TCL-6Dn was thawed, washed 
twice and viable cells were counted by trypan blue staining. TCL-6Dn was 
resuspended in T cell assay medium at 3 x 105/ml. One hundred J.Ll ofTCL-6Dn was 
co-cultured with triplicates of the peptide-pulsed or un-pulsed APCs. In addition, 
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triplicates ofTCL-6Dn was added to wells containing media which received either no 
treatment, 30 TJg/ml OKT3 with 50 U/ml rhiL-2 or 1 Jlg/ml of peptide. All cultures 
were incubated at 37°C in a 6.5% C02 humid chamber for 72 h. During the last 16 h 
of co-culture, each well was pulsed with 1.0 Jl Ci/well of tritiated thymidine eH-
thymidine, 6.7 ci/mmol; Amersham Pharmacia Biotech, Piscataway, NJ, USA). 
After 72 h co-culture 0.25% trypsin was added to each well for 3-5 min, to 
remove adherent cells, cultures were harvested onto 90 x 120 mm printed filtermatA 
glass fiber filters (Wallac, Turku, Finland), using the Harvester 96 Mach III M 
(Tometec, Hamden, CT, USA) and dried in the microwave for 2 min. Filtermats were 
placed on OmniFilter holders (Packard Bioscience Company, Meridian, CT, USA), 35 
Jll of Microscint (Packard Bioscience Company) was added to each well and 3H-
thymidine incorporated into dividing cells was measured using the TopCount NXT 
Microplate Scintillation and Luminescence Counter (Packard Bioscience Company). 
Results were expressed as mean cpm values or stimulation indexes (SI). The SI was 
calculated as follows; SI= Mean cpm of TCL-6Dn + APC + peptide/Mean cpm of 
TCL-6Dn + APC. 
2. 7 .4. Cytokine Response of TCL-6Dn 
APCs were diluted in T cell assay medium to attain 5.6 x 104/ml, 1 ml was 
plated in a 24-well plate (Fisher Scientific) and pulsed with 1 Jlg/ml peptide or un-
pulsed for 2 h. During the peptide-pulsing period, an aliquot of TCL-6Dn was thawed, 
washed twice, counted and resuspended in T cell assay medium to attain 1. 7 x 105 
cells/mi. One ml of TCL-6Dn was co-cultured with peptide-pulsed or un-pulsed 
APCs for 18 h. 
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In addition, cultures of TCL-6Dn (5 x 105/ml) were either un-stimulated, 
stimulated with aT cell mitogen (PHA; 5 J..lg/ml, Sigma) or peptide-pulsed (10 J..lg/ml). 
Positive control cells for each cytokine included C10MJ, for IFN-y, TNF-a and GM-
CSF and PHA-stimulated (5 J..lg/ml) PBMCs for IL-2, IL-4, IL-10 and TGF-~. Newly 
synthesized cytokines produced by the cells were trapped intracellularly using a Golgi 
stop, Brefeldin A (10 J..lg/ml; Sigma), which was present for the full18 h incubation. 
2.7.4.1. Intracellular Cytokine Detection by Flow Cytofluorometry 
To assess production of cytokines, cells were fixed and permeabilized using a 
Fix & Perm kit (Caltag Laboratories). Cells were collected from the twenty-four well 
plates (See section 2.7.4) and placed in 15 ml polypropylene centrifuge tubes, which 
were centrifuged at 300 g, 4°C for 7 min. Next, they were washed in 7 ml of ice-cold 
wash buffer containing 0.1% sodium azide (BDH Biochemicals, Toronto, ON, 
Canada) and 5% FCS in PBS and resuspended at 2 x 106/ml in wash buffer. 
Fifty J..ll of cell suspension was mixed with a pre-determined amount (Table 
2.5) of PE-conjugated mAb, anti-CD4 or mlgG2a isotype control, in 12 x 75 mm 
tubes, vortexed gently and incubated in the dark for 15 min at room temperature (RT). 
Cells were fixed in 100 J..ll of fixation medium, incubated for 15 min at RT in the dark 
and washed twice in 3 ml of ice-cold wash buffer at 300 g for 5 min at 4°C. Cells 
were permeabilized with 100 J..ll of permeabilization medium containing a pre-
determined amount (Table 2.4) of the relevant anti-cytokine or isotype control FITC-
conjugated mAb. Un-conjugated mAbs were optimally diluted in 100 J..ll of 
permeabilization medium. Each sample was vortexed gently and incubated in the dark 
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for 20 min at 4°C. Cells were washed twice in 3 ml of ice-cold wash buffer as 
described above, fixed in 1% PFA and analyzed as described in section 2.5.3.1. 
2.7.5. Cytotoxic Response ofTCL-6Dn 
2.7.5.1. 51Cbromium Release Assay 
Tumor cells were harvested, washed and resuspended in T cell assay medium 
to attain 1 x 106/ml. Thereafter, tumor cell pellets (1 x 106 cells) were incubated with 
100 J.LCi (25 J.Ll) of Na251 Cr04 (sodium chromate; Amersham Biosciences 250 
mCilmg) at 3rc with 6.5% C02 for 90 min. 51Cr-labelled target cells were washed 
four times (one 10 ml wash and three 5 ml washes) with PBS containing 1% FCS. 
Target cell pellets were resuspended in T cell assay media to attain 1.0 x 105 
targets/ml and 50 J.Ll of tumor targets were added to wells of a 96-well u-bottom plate, 
containing 30 J.Ll ofp883 peptide (at 1 J.Lg/ml) or 30 J.Ll of assay medium and incubated 
at 37°C with 6.5% C02 for 2 h. TCL-6Dn was thawed, washed and resuspended in 
assay medium to attain 1.2 x 106 cells/mi. Effector cells (TCL-6Dn) were cultured 
with 51Cr-labelled tumor cells at effector:target ratios of 12:1, 6:1 3:1 and 0:1. Thus, 
50 J.Ll, 25 J.Ll or 12.5 J.Ll of effector T cells were added to wells containing the p883-
pulsed or un-pulsed tumor targets. To determine the spontaneous and maximum 51Cr-
release, target cells were cultured with either 250 J.Ll of assay medium or 250 J.Ll of 1M 
HCl, respectively. Effector T cells and 51 Cr-labelled tumor cells were co-cultured for 
5 hat 37°C with 6.5% C02• A 125 J.Ll aliquot of supernatant was then removed from 
each well and 51Cr release was measured using a gamma counter (Wallac 1480 
Wizard, Perkin Elmer). Percent specific lysis was calculated using the following 
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formula: (experimental 51Cr-release - spontaneous 51 Cr-release I maximum 51Cr-
release- spontaneous 51Cr-release) x 100. 
2.7.5.2. JAM Assay (Thymidine Release Assay) 
Tumor cells were removed from culture and pre-incubated with 5.0 J.LCi/ml of 
3H-thymidine in a 15 ml polypropylene tube (1 x 106 cells/1 Oml) for 18 h. Cells were 
washed three times in enriched IMDM and resuspended in T cell assay medium to 
attain 1 x 105/ml. One hundred J.Ll of APCs were pulsed with peptide (1 J.Lg/ml) or un-
pulsed for 2h. During the peptide-pulsing period, an aliquot of TCL-6Dn was thawed, 
washed twice, counted and resuspended in T cell assay medium to attain 3.0 x 105 
cells/mi. Peptide-pulsed and un-pulsed APCs were co-cultured with 100 J.Ll of TCL-
6Dn or 100 J.Ll of medium for 48 h. All cultures were performed in triplicates in a 96 
well u-bottom plate. 
After 48h co-culture, 0.25% trypsin was added to each well for 3-5 min, to 
ensure all adherent cells were detached from the plastic, and target cell lysis was 
evaluated by measuring the amount of 3H-thymidine remaining in the target cells (as 
described in section 2. 7.3). Specific lysis due to TCL recognition of exogenous p883 
was calculated as [(cpm p883-pulsed APC)- (cpm p883-pulsed APC + TCL) I (cpm 
p883-pulsed APC)] x 100%. Specific lysis due to recognition of endogenously 
produced Her-2 p883 was calculated as [(cpm APC) - (cpm APC + TCL) I (cpm 
APC)] x 100%. 
2. 7.6. Tumor Cell Proliferation Assay 
Do-irradiated tumor cells were resuspended in T cell medium at 1 x 105 /mi. 
One hundred J.ll of tumor cells were plated in wells of a 96-well u-bottom plate and 
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pulsed with 1 Jlg/ml of peptide or un-pulsed for 2 h. During the peptide-pulsing period 
an aliquot of TCL-6Dn was thawed, washed, counted and resuspended in T cell assay 
medium to attain 3 x 105 cells/mi. One hundred f.ll of TCL-6Dn was co-cultured with 
peptide-pulsed or un-pulsed tumor cells for 72 h. During the last 16 h of co-culture, 
each well was pulsed with 1.0 J.!Cilwell of 3H-thymidine. Cell cultures were 
trypsinized, harvested and 3H-thymidine incorporated into tumor cells was measured, 
as described in section 2.7.3. Results were expressed as mean cpm values of triplicate 
wells. Percent inhibition was calculated as 100 minus [(cpm APC + TCL-6Dn I cpm 
APC) x 100] or 100 minus [(cpm p883-pulsed APC + TCL-6Dn I cpm p883-pulsed 
APC) x 100]. 
2. 7. 7. Transwell Assay 
Non-irradiated tumor cells were resuspended in T cell assay medium at 7.0 x 
104/ml. Eight hundred J.ll of tumor cells (5.6 x 104 cells) were plated in a 24-well flat-
bottom plate, designed for use with cell culture inserts (Falcon, Becton Dickinson, 
Franklin Lakes, NJ) and pulsed with 1 Jlg/ml of peptide or un-pulsed for 2 h. 
Duplicate wells of tumor cells were set up to allow culture of tumor cells and TCL-
6Dn without and with a 0.4 Jlffi cell culture insert (Falcon) present. During the 2 h 
peptide-pulsing period an aliquot of TCL-6Dn was thawed, washed, counted and 
resuspended in assay medium to attain 5.6 x 105 /ml. Three hundred f.ll of TCL-6Dn 
(1.68 x 105 cells) was co-cultured, without a cell culture insert present, with tumor 
cells. In addition, TCL-6Dn was placed in a cell culture insert and cultured with tumor 
cells, preventing cell contact between tumor cells and TCL-6Dn. As a control, 300 Jll 
ofT cell assay media was added directly to tumor cells or placed in the cell culture 
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insert. During the last 16 h of a 72 h culture period, each well was pulsed with 1.0 
J.!Cilwell of 3H-thymidine. For wells containing the cell culture insert, 3H-thymidine 
was added below the insert. Thereafter, cell culture inserts were removed, cells were 
trypsinized and equally distributed into five wells of a 96 well u-bottom plate. Cells 
were harvested and 3H-thymidine incorporated into cells was measured, as described 
in section 2.7.3. Results were expressed as mean cpm values of five wells. Percent 
Inhibition was calculated as 100 minus [(cpm APC + TCL-6Dn I cpm APC) x 100] or 
100 minus [(cpm p883-pulsed APC + TCL-6Dn I cpm p883-pulsed APC) x 100]. 
41 
CHAPTER3.RESULTS 
3.1. Determination of TCL-6Dn specificity 
TCL-6D was previously shown to proliferate in response to 2.5 J.lg/ml of Her-
2 p883 presented by DR~1 *0401+ DCs, PBMCs and L cells (Kobayashi et al., 2000). 
To confirm the specificity of expanded TCL-6D, now called TCL-6Dn, and the 
optimal peptide concentration required for its activation, we performed proliferation 
assays using DR~ 1 *040 1 + and DR~ 1 *040 1- APCs and p883 from 0.01 J.lg/ml to 10 
J.lg/ml. As shown in Figure 3.1A, the highest proliferative responses of TCL-6Dn 
were attained with p883 at 1 ~ml using DR~1 *0401 + and *0402+ L cells. 
Meanwhile, TCL-6Dn responded poorly to homozygous DR4+ B-cell lines at all 
peptide concentrations. Indeed, the SI values were only slightly higher than those 
attained using DR~ 1 * 1501 + APCs, which were not expected to stimulate TCL-6Dn. 
The low SI values were not due to poor HLA-DR expression as all cell lines had 
abundant levels of HLA-DR (Fig 3.1B). Since these data suggested that the affinity 
and possibly the specificity of TCL-6Dn may be different from those of the original 
TCL-6D clone, we performed several experiments using DCs as APCs and 
phenotyped TCL-6Dn. 
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Figure 3.1. TCL-6Dn proliferation in response to APCs pulsed with various 
concentrations of p883. (A) Irradiated APCs were pulsed with concentrations of 
p883 from 0.01 ~g/ml to 10 ~g/ml and cultured with TCL-6Dn. Stimulation indexes 
were calculated based on the mean cpm of triplicate wells. (B) HLA-DR (mAb 
L243; open histogram) expression on BCLs and L cells was detected by flow 
cytofluorometry. The negative isotype (mlgG2a) control is gray. Data shown are 
representative of two experiments. 
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3.2. Phenotype of TCL-6Dn 
Expression of cell surface markers on un-stimulated TCL-6Dn was detected 
by flow cytofluorometry. PBMCs were included as a positive control cell population. 
As shown in Figure 3.2, TCL-6Dn expressed CD2, CD3, CD4, CD56 and an a:~ T-
cell receptor (TCR). The presence of CD25, CD38, CD69, CD45RO and CD28 
indicated an activated T cell phenotype. In addition, TCL-6Dn expressed the HLA 
class II molecules, HLA-DR, -DP, -DQ, and co-stimulatory molecules CD80 and 
CD86. Further assays performed in Dr. Drover's laboratory showed TCL-6Dn also 
expressed intracellular HLA-DM and Ii (data not shown). The absence of CDS, y:C> 
TCR, CD16 and CD45RA expression on TCL-6Dn were not due to poor antibody 
binding as cell populations expressing these antigens were present in the PBMCs 
positive control. 
Due to CD25 expression on TCL-6Dn, we also tested for FOXP3 and showed 
that TCL-6Dn expressed mRNA for FOXP3 (Figure 3.3). However, Yagi et al. (2004) 
have shown memory T cells in human PBMCs express low but detectable levels of 
FOXP3 mRNA, which can be up-regulated by anti-CD3 and anti-CD28 stimulation. 
Altogether, TCL-6Dn was considered to be an activated CD4+ T cell clone. 
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Figure 3.2. TCL-6Dn expressed an activated CD4' T cell phenotype. Cell Stu-face 
markers expressed on TCL-6Dn (red line) and PBMCs (dotted-black line) were 
examined by flow cytofluorometry. Negative control (non-specific mlgG v.;th TCL-
60n) is shown in gray. Histograms show fluorescence values of gat<..-d viable cells. 
Data shown are representative of two experiments. 
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Figure 3.3. TCL-6Dn expressed FOXPJ mRNA. FOXP3 1111DSCripts were detected by 
RT-PCR in cON As prepared from purified mRNAs from TCI..-6Dn, PBMCs, Jurlcat, 
SAVC and CIOMJ as described in section 2.6. Sterile li20 was used as a negative 
control and D-actin was included as a housekeeping gene. 
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3.3. HLA-DR Restriction and Peptide Specificity of TCL-6Dn 
Although TCL-6D was previously shown to recognize p883 presented by 
DRP1 *0401 molecules (Kobayashi et al., 2000), our preliminary experiment (Figure 
3.1) suggested TCL-6Dn had a more complex specificity. To clarify the HLA-DR 
restriction of TCL-6Dn, proliferation assays were performed using p883 and 
immature or mature DCs from DRP1 *0401+ and DRP1 *0401" healthy donors. Using 
flow cytofluorometry, we confirmed that immature DCs expressed moderate levels of 
CD40 and HLA-DR and low levels of CD83 and CD86, while mature DCs expressed 
higher levels ofCD40, CD83, CD86 and HLA-DR (Figure 3.4). 
Surprisingly, TCL-6Dn recognized p883 presented by mature and immature 
DCs from both DRP1 *0401,07;DR53 and DRP1 *1501,1301; DR51,DR52 donors 
(Figure 3.5). Although TCL-6Dn proliferation was higher with p883-pulsed 
DRP1 *0401+ DCs, p883-pulsed DRP1 *0401" DCs were not expected to stimulate 
TCL-6Dn. Since these donors did not share common HLA-DR molecules, the results 
suggested that TCL-6Dn displayed degenerate HLA-DR restriction. Alternatively, 
since TCL-6Dn expressed abundant HLA-DR (Figure 3.2) TCL-6Dn may act as an 
APC. 
To further evaluate TCL-6Dn's specificity, we performed proliferation assays 
using mature DRP1*0401+ DCs pulsed with p883 or an irrelevant peptide. As shown 
in Figure 3.6, TCL-6Dn did not respond to un-pulsed or irrelevant peptide-pulsed 
DCs, while moderate proliferation responses were attained with p883-pulsed DCs. 
However, due to lower background cpms, our calculated SI values were similar to 
those attained by Kobayashi et al. (2000). 
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Figure 3.4. Phenotype of in-vilro-generated DCs. The phenotype of immarure (red 
line) and mature (blue line) DCs (generated •• described in section 2.4) were 
examined hy now cytolluorometry. Binding of unlabelled mAbs specific for COla, 
CD40, CD80, CD83, CD86 aod HLA-DR were detected using PE-conjugated GAM. 
NcS~Ilive controls, mlgG I or mlgG2a, ore shown in gray. Histograms show 
nuorescence values of gated viable cells. 
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Figure 3.5. TCL-6Dn proliferated in response to p883 presented by DR~l *0401+ 
(D~l *0401,07;DR53) and DR~ I *0401- (DR~l *1501,1301;DR51,DR52) DCs. 
Mature (M) and immature (I) DCs from healthy donors were mitomycin C treated, 
pulsed with p883 (1 Jlg/ml) and cultured with TCL-6Dn for 72 h. Proliferation of DCs 
and TCL-6Dn in the absence ofp883 (black bars) or presence ofp883 (gray bars) was 
measured as described in section 2.7.3. Each bar represents the mean and SD of 
triplicate wells. 
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Figure 3.6. TCL-6Dn proliferation in response to DRPl *0401+ DCs was p883-
specific. Mature DCs from a DRPl *0401+ healthy donor were irradiated, pulsed with 
p883 or an irrelevant peptide and co-cultured with TCL-6Dn for 72 h. Proliferation of 
TCL-6Dn in response to un-pulsed DCs (black bars) p883-pulsed DCs {lflg/ml; gray 
bars) or irrelevant peptide-pulsed DCs (1 f.!g/ml; striped bars) was measured as 
described in section 2. 7.3 Each bar represents the mean and SD of triplicate wells. 
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Meanwhile, since TCL-6Dn retained its specificity for p883, we attempted to 
determine ifTCL-6Dn also recognized p883 presented by HLA-DR4+ tumor cells. 
3.4. Characterization of Human Tumor Cell Lines used as APCs 
3.4.1. Her-2 Expression on Tumor Cell Lines 
TCL-6Dn was tested for its ability to recognize tumor cell lines naturally 
expressing the Her-2 protein. For this purpose, Her-2+ (T47D and HT29) and Her-2-
(MDA MB 435) tumor cell lines were chosen. As shown in Figure 3.7, surface 
expression of Her-2 was undetectable on all cell lines tested. However, intracellular 
Her-2 was detected in HT29 and T47D whereas Her-2 was undetectable in MDA MB 
435. These results were confirmed by immunocytochemistry (data not shown). 
3.4.2. HLA-Class II Expression on Tumor Cell Lines 
Generally, tumor cell lines do not constitutively express HLA-DR or express 
very low levels (see Table 2.1). Therefore, up-regulation of HLA-class II molecules 
was induced with rhlFN-y. Un-transfected and DRPl *0401-transfected human tumor 
cell lines, were tested for constitutive (NI) and induced (I) expression of HLA-DR, 
HLA-DR4, HLA-DM and invariant chain (Ii). 
As shown in Table 3.1, HT29 and T47D did not constitutively express HLA-
DR, while MDA MB 435 expressed low levels of DR molecules. HLA-DR was up-
regulated on the three cell lines with IFN-y treatment; as expected HLA-DR4 was 
also up-regulated on the DR4+ lines, MDA MB 435 and HT29. 
51 
Un-permeabilized Permeabilized 
.... OJ 
<0 N 
~ 
., ., 
T47D c c ., ., 
> > 
w w 
010D 10' 102 103 10. 103 10. 
PE 
.... .... 
<0 CD 
., ., 
HT29 c c ., ., 
> > 
w w 
010D 10' 102 103 10. 103 10. 
PE 
OJ OJ 
~ ~ 
., ., 
MDAMB435 c c ., ., 
> > 
w w 
102 103 10. 102 103 10. 
PE PE 
.... OJ 
CD ~ 
., ., 
SKBR3 c c ., ., 
> > 
w w 
102 103 10. 010D 10' 103 10. 
PE 
Figure 3.7. Intracellular and surface expression of Her-2 in tumor cell lines. Her-2 
expression was detected by flow cytofluorometry in non-induced T47D, HT29 and 
MDA MB 435. Histograms show Her-2 expression (in black) and the negative control 
mlgGl (in gray). SKBR3 is the positive control tumor cell line for Her-2 expression. 
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Table 3.1. Constitutive (NI) and IFN-y induced (I) HLA-DR, HLA-DR4, HLA-DM 
and Ii expression on human tumor celllinesd. 
Cell Linea HLA-DRb HLA-DR4b HLA-DMb Invariant 
Chainb 
HT29 (NI) 0 0 1.8 13 
HT29 (I) 4,354 2,031 145 230 
HT29-*0401 (NI) 1,283 472 0 34 
HT29-*0401 (I) 4,614 915 77 288 
T47D (NI) 9.4 0 0 41 
T47D (I) 6,842 83 143 396 
T47D-*0401 (NI) 2,425 1,771 0 17 
T47D-*0401 (I) 5,298 2,142 66 251 
MDA MB 435 (NI) 682 22 10 101 
MDA MB 435 (I) 5,604 2,232 158 240 
MDA MB 435-*0401 (NI) 5,707 4,936 20 64 
MDA MB 435-*0401 (I) 6,696 8,061 174 180 
SAvcc 2,945 2,160 114 309 
a Flow cytofluorometric analysis was performed on un-transfected and HLA-DRf31 *040 1 transfected 
tumor cell1ines (T47D, HT29, MDA MB 435). 
b The mean fluorescence intensity (MFI) of the negative control mAbs, non-specific IgG 1 and lgG2a, 
were subtracted from the MFI of the antigen specific mAbs. 
c Control human B cell line was SA VC. 
d Data shown represents one of two experiments performed. 
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Results also confirmed the DR~1 *0401-transfected tumor cell lines (NI and I) 
expressed the DR~1 *0401 molecules. 
Constitutive and induced expression of class II co-chaperones, HLA-DM and 
li, were assessed by intracellular flow cytofluorometry. Low levels of Ii were 
expressed constitutively by all tumor cell lines (Table 3.1). However, constitutive Ii 
expression was higher in T47D and MDA MB 435 compared to HT29. IFN-y 
treatment of all tumor cell lines resulted in up-regulation of this co-chaperone. HLA-
DM was not constitutively expressed by HT29 and T47D, but MDA MB 435 
expressed low levels ofHLA-DM (Table 3.1). Meanwhile, HLA-DM expression was 
up-regulated by all IFN-y-treated tumor cells. 
3.5. Non-Proliferative Response of TCL-6Dn to p883 Presented by Tumor Cell 
Lines 
TCL-6Dn was tested for its ability to recognize p883-pulsed or un-pulsed Her-
2+ and Her-2- tumor cell lines. All tumor cells (NI and I) were irradiated and cultured 
with TCL-6Dn with or without exogenous p883. Although the tumor cell lines were 
exposed to 20,000 rads prior to co-culture with TCL-6D, we were unable to 
completely inhibit tumor cell proliferation. We tested the ability of mitomycin C and 
various doses of gamma irradiation (y4200, y8400, y12600 and y20000 rads) to 
inhibit tumor cell proliferation and the lowest proliferation was observed when tumor 
cell lines were exposed to 20,000 rads of gamma irradiation (data not shown). In 
addition, we also examined the effect of cell density at the time of irradiation 
whereby 5 x 105 or 1 x 106 tumor cells/tube were exposed to y20,000 rads. We have 
not shown this data, but the cell density did not affect tumor cell irradiation. 
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We continued to examine whether TCL-6Dn proliferated in response to p883-
pulsed or un-pulsed Her-2+ and Her-2- tumor cell lines. Our results in Figure 3.8, 
showed that TCL-6Dn failed to proliferate to p883 presented by DR~ I *0401 + and 
DR~1 *0401- tumor cells. Indeed, co-cultures of TCL-6Dn with p883-pulsed HLA-
DK [HT29 (NI) and T47D (NI)] and HLA-DR+ tumor cell lines [HT29-*0401 {1), 
T47D (1), T47D-*0401 (NI and I) and MDA MB 435-*0401 (NI and I)] had lower 
cpm values than tumor cells cultured alone. The lowest proliferation was observed 
when IFN-y-treated DR~ 1 *040 1-transfected tumor cells were cultured with TCL-
6Dn, suggesting TCL-6Dn prevented tumor cell growth. 
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Assay controls were included in all proliferation assays, showing that TCL-
6Dn proliferated with anti-CD3 and IL-2 treatment, but did not proliferate with p883 
alone. Consequently, these results may address why TCL-6Dn proliferated when DCs 
were used as APCs. Activated DCs generate IL-12, which may send a survival signal 
to TCL-6Dn, resulting in IL-2 production. However, our data showed that p883-
loaded and PHA-stimulated TCL-6Dn did not generate IL-2 (data not shown) and 
were unable to stimulate TCL-6Dn to proliferate. 
When p883-loaded tumor cell lines and TCL-6Dn were co-cultured together 
we know that TCL-6Dn failed to proliferate. Since both TCL-6Dn and tumor cells 
expressed HLA-DR, TCL-6Dn may recognize p883 presented by either the peptide-
loaded tumor cells or peptide-loaded TCL-6Dn. Meanwhile, our data suggested that 
TCL-6Dn recognized the p883 and inhibited tumor cell growth or initiated tumor cell 
death. Tumor cells used in this study were resistant to irradiation and required at least 
12600 rads to inhibit cell growth (data not shown). Even at 12600 rads, we still 
detected tumor cell proliferation. Consequently, we decided to test the affect of TCL-
6Dn on tumor cell growth by co-culturing TCL-6Dn with non-irradiated tumor cell 
lines. 
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3.6. Inhibition of Tumor Cell Proliferation by TCL-6Dn 
To confirm that TCL-6Dn inhibited tumor cell growth we performed 
proliferation assays using non-irradiated tumor cells as APCs. As shown in Figure 
3.9, nearly all p883-pulsed tumor cells had significantly lower proliferation when 
cultured with TCL-6Dn. Unexpectedly, TCL-6Dn decreased the proliferation of 
p883-pulsed HLA-DR cell lines HT29 and T47D, but inhibition of proliferation was 
most notable with HLA-DR+ tumor cells. Indeed, DR+ cell lines (non-DR~1 *0401) 
HT29 (I) and T47D (I) growth was inhibited by 95% and 52%, respectively, while 
MDA MB 453 (I) was slightly inhibited by 24%. All DR~1 *0401+ cell lines (NI and 
I) were significantly inhibited by TCL-6Dn, though inhibition was higher in HT29-
*0401 (I) and T47D-*0401 (I). In addition, except for MDA MB 435, the inhibition 
of DR~*040 1 + tumor cells was more pronounced in IFN-y induced cell lines 
compared to their non-induced counterparts, suggesting that IFN-y may pre-condition 
the tumor cells to undergo cell death or inhibit cell growth. 
Un-pulsed HLA-DR tumor cell lines (HT29, T47D and MDA MB 435) were 
not affected by TCL-6Dn; showing that TCL-6D did not inhibit tumor cell growth 
non-specifically. Similarly, unpulsed DR+ (*0401-) tumor cells showed no significant 
reduction in growth when cultured with TCL-6Dn. Proliferation of un-pulsed, 
DR~1*0401+, non-induced tumor cells were slightly inhibited by TCL-6Dn. 
However, TCL-6Dn significantly inhibited the proliferation of un-pulsed 
DR~1 *0401+, IFN-y induced cell lines HT29 and MDA MB 435. These results 
suggested HT29 and MDA MB 435, but not T47D, processed endogenous Her-2 
protein and presented the p883 epitope by DR~1 *0401 molecules to activate TCL-
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6Dn. Inhibition of MDA MB 435 cell growth by TCL-6Dn was unexpected as this 
cell line was Her-2 negative. 
All tumor cell lines proliferated strongly in the absence of TCL-6Dn. 
Meanwhile, trumor cells that were cultured with IFN-y displayed reduced cell growth 
compared to the non-IFN-y-induced tumor cells as determined by microscopic 
examination and cell counts (data not shown). This is likely due to the inhibitory 
effect of IFN-y on tumor cell growth. 
TCL-6Dn appeared to recognize p883, causing tumor cell lysis or inhibition 
of tumor cell growth. However, proliferation of tumor cells cultured with p883 did 
not differ compared to tumor cells cultured alone, indicating the peptide was not 
cytotoxic (data not shown). Thus far, our data has shown that TCL-6Dn proliferated 
strongly to p883 presented by DCs, but in the presence of p883-loaded APCs TCL-
6Dn inhibited tumor cell proliferation. 
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Figure 3.9. TCL-6Dn inhibits proliferation of non-irradiated, p883-pulsed tumor 
cells. Tumor cell lines were treated or not with IFN-y and used as APCs. Proliferation 
of APCs alone (black bars), APCs and TCL-6Dn in the absence ofp883 (gray bars) or 
presence ofp883 (1 J.tg/ml; striped bars) was measured as described in section 2.7.6. 
Each bar represents the mean and standard deviation of triplicate wells. Statistical 
significance (*), (p< 0.05) was determined using the paired t-test. % inhibition is 
shown above each bar and calculated as described in section 2.7.6. Data shown 
represents one of two experiments performed. 
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3.6.1. Increasing the concentration of p883 augments the effect of TCL-
6Dn on tumor cell growth 
To determine the concentration of peptide required for TCL-6Dn to inhibit 
tumor cell proliferation, proliferation assays using non-irradiated tumor cells and 
p883 from 0.1 J.lg/ml to 5.0 J.lg/ml were performed. As shown in Figure 3.10, as the 
concentration ofp883 increased, proliferation oftumor cells decreased when cultured 
with TCL-6Dn. However, greatest inhibition (97%) was observed when TCL-6Dn 
was cultured with HT29 (I) and HT29-*0401 (NI and I) and 0.5, 1.0 or 5.0 J..lg/ml of 
p883. TCL-6Dn also inhibited proliferation of p883-pulsed HLA-DK HT29, 
indicating presentation of p883 to TCL-6Dn does not involve HLA-DR on the tumor 
cells. However, we cannot rule out the involvement of HLA-DR in antigen 
presentation of the p883 peptide as TCL-6Dn cells may be acting as APCs and 
presenting p883 to other TCL-6Dn cells in the context ofHLA-DR molecules. 
In summary, these results led us to ask whether TCL-6Dn lysed tumor cells 
and whether this was cytokine mediated or contact-dependent. Therefore, as a first 
step we examined the cytokines produced by activated TCL-6Dn. 
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Figure 3.10. Increasing the concentration of p883 increases the inhibition of tumor 
cell growth by TCL-6Dn. Tumor cell lines (non-induced and IFN-y-induced) were 
cultured alone or cultured with TCL-6Dn and [p883] from 0 J..l.g/ml to 5 J..l.g/ml. The% 
inhibition was calculated as described in section 2.7.6. Data shown are representative 
of two experiments. 
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3.7. Cytokines Produced by Activated TCL-6Dn 
Cytokines produced by TCL-6Dn were detected by intracellular flow 
cytofluorometry. For these assays TCL-6Dn was cultured with DR~ 1 *040 1 + tumor 
cells and p883 for 18 h in media containing brefeldin A (10 J..Lg/ml; BFA). Thereafter, 
cytokine producing T cells were detected using PE-conjugated anti-CD4 and FITC-
conjugated cytokine-specific mAbs. As a control, TCL-6Dn was also cultured with 
and without a T cell mitogen (PHA; 5 J..Lg/ml). 
3.7.1. TCL-6Dn Produces IFN-y in Response to p883-pulsed Tumor Cells 
To determine the cytokine profile, TCL-6Dn was cultured with p883-pulsed 
and un-pulsed tumor cell lines (T47D*0401, HT29*0401, and MDA MB 435*0401). 
Cytokine-producing T cells were detected using CD4- and IFN-y-specific mAbs. As 
shown in Figure 3.11A, IFN-y was undetected when TCL-6Dn was cultured with un-
pulsed tumor cells, but TCL-6Dn responded to p883-pulsed tumor cells, resulting in 
IFN-y production (Figure 3.11B). Although the % IFN-y+ T cells was low (8% to 
12%) when cultured with p883-pulsed tumor cells, assay controls showed 48.8% of 
PHA-stimulated TCL-6Dn produced IFN-y, but without stimulation TCL-6Dn did not 
produce IFN-y (Figure 3.11C). 
IFN-y generated by TCL-6Dn in response to p883-pulsed HT29-*0401 and 
MDA MB 435-*0401 was tested once, but this assay was repeated with p883-pulsed 
T47D*0401 and similar results were obtained. In addition, this assay included TCL-
6Dn cultured with and without p883 in the absence of tumor cells. p883-pu1sed TCL-
6Dn produced IFN-y (data not shown), suggesting that TCL-6Dn presented p883 in 
the context ofHLA-DR molecules resulting in activation of other TCL-6Dn cells. 
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Figure 3.11. TCL-6Dn produced IFN-y in response to p883-pulsed tumor cell lines. 
Un-pulsed (A) and p883-pulsed (B) tumor cells were cultured with TCL-6Dn in media 
containing BFA (10 J.lg/ml) for 18h. (C) Un-stimulated and PHA-stimulated (5 J.lg/ml) 
TCL-6Dn were used as controls. Cells were stained with (i) mlgG2a-PE & mlgG 1-
FITC isotype controls mAbs or (ii) CD4-PE & IFN-y-FITC antigen-specific mAbs. 
10,000 events were acquired. Dot plots show fluorescence of gated cells and 
percentage of FITc+pE+ cells. Quadrant locations were determined based on the 
appropriate negative controls. 
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3.7.2. Cytokines Produced by TCL-6Dn in Response to p883-Activation 
Since TCL-6Dn expressed abundant levels of class II molecules and based on 
our previous data, we asked whether TCL-6Dn was auto-activated by p883 to 
produce cytokines capable of inhibiting tumor cell growth. TCL-6Dn was PHA-
stimulated or p883-pulsed, in the absence of APCs, and tested for intracellular IFN-y, 
IL-2, IL-4, IL-10, GM-CSF, TNF-a and TGF-~. As shown in Figure 3.12, un-
stimulated TCL-6Dn did not produce cytokines, but PHA and p883 stimulated a high 
number of TCL-6Dn cells to produce IFN-y, TNF-a and GM-CSF while a low 
number of TCL-6Dn cells produced IL-4. C10MJ was a positive control cell line in 
this assay and constitutively produced IFN-y, TNF-a and GM-CSF. Although a 
positive control for IL-2, IL-10 and TGF-~ was not shown, prior to this assay these 
cytokines were detected in PHA-stimulated PBMCs, proving the mAbs were capable 
of binding to the specific cytokines. 
To ensure that activation of TCL-6Dn and production of cytokines was p883 
specific, we examined cytokines produced by TCL-6Dn when cultured with an 
irrelevant HIV peptide. As shown in Figure 3.13, TCL-6Dn did not respond to the 
irrelevant peptide, but was stimulated by p883. These results showed TCL-6Dn 
activation was p883-specific and may involve auto-activation with p883 loaded onto 
HLA class II molecules on TCL-6Dn. 
In summary, TCL-6Dn proliferated in response to p883-pulsed DCs, but not 
p883 alone or p883-pulsed tumor cells. Possibly IL-12 generated by the DCs, but not 
other APCs, may stimulate activated T cells to produce IL-2 and proliferate. 
Meanwhile, p883-pulsed TCL-6Dn produces Th1 cytokines, IFN-y, TNF-a and GM-
CSF, which may inhibit tumor cell growth or causes tumor cell lysis. 
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Figure 3.12. p883 activated TCL-6Dn to produce IFN-y, TNF-a, GM-CSF and IL-4. 
TCL-6Dn was cultured in media containing BFA (10 J.tg/ml) and either un-stimulated, 
PHA-stimulated (5 J.tg/ml) or p883-pulsed (1 J.tg/ml). C10MJ was used as a positive 
control in this assay. T cells were tested for intracellular cytokines following 18h 
culture using FITC-conjugated cytokine-specific mAbs. 20,000 events were acquired 
and values show the % of FITC positive cells in the gated cell population. Quadrant 
locations are determined based on the appropriate negative control shown above each 
cytokine-specific mAb. 
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Figure 3.13. TCL-6Dn was not stimulated by an irrelevant peptide to produce 
cytokines. TCL-6Dn was cultured in media containing BFA (10 Jlg/ml) and either 
un-stimulated, PHA stimulated (5 Jlg/ml), p883 pulsed (1 Jlg/ml) or irrelevant 
peptide pulsed (1 Jlg/ml). T cells were tested for intracellular IFN-y, 1NF-a and 
GM-CSF following 18h culture using FITC-conjugated cytokine-specific mAbs. 
15,000 events were acquired and values show the percent of FITC positive cells in 
the gated cell population. Data shown are representative of two experiments. 
Quadrant locations are determined based on the appropriate negative control. 
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3.8. Antibody Blocking Studies to Determine the Involvement of Class II 
Molecules in TCL-6Dn Activation 
Kobayashi et al (2000) showed TCL-6D recognized p883 presented by HLA-
DR(H *0401 molecules, whereas our data suggested that TCL-6Dn displayed 
promiscuous HLA-DR restriction. Potentially, TCL-6Dn may recognize p883 
presented by HLA-DR, -DP or -DQ molecules. Therefore, various assays were 
performed using blocking antibodies specific for HLA class I and class II molecules 
to determine how TCL-6Dn recognized p883. These assays were performed using 10 
~g/ml of mAbs, as performed by Kobayashi et al (2000). 
3.8.1. TCL-6Dn Proliferation in Response to p883-pulsed PBMCs was not 
inhibited by HLA maAbs 
To determine the involvement of HLA-DR in TCL-6Dn activation, we 
performed proliferation assays using p883 and DR~1 *0401+ PBMCs treated with 
mAbs specific for HLA class I, HLA-DP, -DQ, -DR, -DR4 and -DR~1 *0401. Non-
specific mlgG 1 and mlgG2a were used as isotype control mAbs. 
As shown in Figure 3.14, in the absence of a mAb, TCL-6Dn responded 
strongly to p883-pulsed DR~1 *0401+ PBMCs. Meanwhile, only M67 (anti-HLA-DP 
mAb) decreased TCL-6Dn proliferation compared to the mlgG1 control mAb, but 
this was not significant. In contrast, L243 (anti-HLA-DR mAb) increased TCL-6Dn 
proliferation compared to the mlgG2a isotype control. Although a clear conclusion 
could not be drawn from these results because both the mlgG 1 and mlgG2a control 
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Figure 3.14. Inhibition of TCL-6Dn proliferation in response to p883-pulsed 
DRP1 *0401+ PBMCs. P883-pulsed PBMCs were cultured without (striped bars) or 
with TCL-6Dn (gray bars) for 72 h. Prior to peptide pulsing PBMCs were incubated 
with various mAbs at 10 J..Lg/ml including, non-specific mlgG1, anti-HLA-DR4 
(NFLD.D1), anti-HLA-DP (M67), non-specific mlgG2a, anti-HLA-DR (L243), anti-
HLA-DRPl *0401 (NFLD.D11) or anti-HLA-Class I (W632) for 30 min. Each bar 
represents the mean and standard deviation of triplicate wells. Data shown are 
representative of two experiments. 
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mAbs decreased TCL-6Dn proliferation, there is no evidence that the HLA class II 
mAbs significantly modulated TCL-6Dn proliferation. 
3.8.2. TCL-6Dn-mediated inhibition of tumor cell proliferation was not 
blocked by anti-HLA-DR mAb 
To determine the involvement of HLA-DR in the inhibition of tumor cell 
proliferation, we cultured TCL-6Dn with p883 and HT29-*0401 treated with anti-
HLA-DR (L243), mlgG2a or without blocking mAb. As shown in Figure 3.15, TCL-
6Dn inhibited proliferation of un-pulsed and p883-pulsed HT29-*040 1. Treatment of 
these tumor cells with either mlgG2a or L243 enhanced the response of TCL-6Dn. 
Indeed, up to 94% of p883-pulsed tumor cell proliferation was inhibited when tumor 
cells were treated with L243. In the absence of TCL-6Dn, addition of mAbs, 
particularly L243, decreased proliferation ofp883-pulsed HT29-*0401, but increased 
proliferation ofun-pulsed HT29-*0401. A plausible explanation is the anti-HLA-DR 
mAb may bind to the p883:HLA-DR~1 *0401 complexes and stimulate the 
production ofTNF-a or up-regulate death-inducing molecules on the tumor cell lines. 
An alternative explanation is that the blocking mAbs may have bound to the Fe 
receptors on TCL-6Dn, resulting in T cell activation. 
Altogether, we were unable to block the interaction between TCL-6Dn and 
tumor cells with L243. Thus, TCL-6Dn may recognize p883 presented by tumor cells 
in an HLA-DR-independent manner. However, we are uncertain whether L243 
completely blocked the T cell and tumor cell interaction, since the mAb would have 
also bound to HLA-DR molecules on TCL-6Dn. 
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Figure 3.15. Treatment of tumor cells with anti-HLA-DR mAb did not affect the 
ability of TCL-6Dn to inhibit tumor cell proliferation. Non-irradiated HT29-*0401 
was un-pulsed or p883-pulsed (1 Jlg/ml) and cultured with or without TCL-6Dn for 
72h. Prior to peptide pulsing or co-culture with TCL-6Dn, tumor cells were incubated 
(A) without mAb present, (B) with mlgG2a (azide free; 10 Jlg/ml) or (C) with anti-
HLA-DR (azide free L243; 10 Jlg/m1) for 30 min. Values above each bar represent the 
% inhibition calculated was calculated as 100 minus [ ( cpm APC + TCL-6Dn I cpm 
APC) x 100] or 100 minus [(cpm p883-pulsed APC + TCL-6Dn I cpm p883-pulsed 
APC) x 100]. Data shown are representative of two experiments. 
73 
3.8.3. Treatment ofTCL-6Dn with anti-HLA-DR mAb prior to p883-
pulsing did not decrease cytokine production. 
To determine whether HLA-DR is involved in p883-activation ofTCL-6Dn, T 
cells were treated with anti-HLA-DR mAb (azide free; L243) or mlgG2a isotype 
control (azide free) for 30 min prior to adding p883. Blocking mAbs were left in 
throughout the culture period. Thereafter, intracellular IFN-y, GM-CSF and TNF-a 
generated by TCL-6Dn were detected by flow cytofluorometry. 
TCL-6Dn alone did not produce cytokines, but p883 stimulated TCL-6Dn to 
produce IFN-y, TNF-a and GM-CSF (Figure 3.16). TCL-6Dn cultured with mlgG2a 
and p883 resulted in slightly higher levels of IFN-y compared to TCL-6Dn cultured 
with p883 alone. However, the percentage ofiFN-y, TNF-a and GM-CSF producing 
cells increased dramatically when TCL-6Dn was cultured with p883 and anti-HLA-
DR. Additional assays showed that mAbs in the absence of p883 did not activate 
TCL-6Dn to produce cytokines (data not shown). The increased cytokine production 
in the presence of peptide and blocking mAbs may have occurred due to antibody 
binding via the Fe receptors, activating TCL-6Dn. Alternatively, anti-HLA-DR mAb 
may bind to DR molecules on TCL-6Dn causing activation and increased cytokine 
production. Altogether, these data show that p883 activated TCL-6Dn, yet the 
mechanism ofanti-HLA-DR in the activation ofTCL-6Dn remained unclear. 
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Figure 3.16. Treatment of TCL-6Dn with anti-HLA-DR mAb prior to p883-pulsing 
did not decrease cytokine production. TCL-6Dn was treated with purified mlgG2a 
mAb (10 lJ.g/ml) or anti-HLA-DR mAb (L243; 10 lJ.g/ml) for 30 min. Thereafter, 
TCL-6Dn was cultured with or without p883 (1 lJ.g/ml). TCL-6Dn was cultured in 
media containing BFA (10 lJ.g/ml) for 18h after which intracellular IFN-y, GM-CSF 
and TNF-a were analyzed by flow cytofluorometry. Values show the percent ofFITC 
positive cells in the gated viable cell population. Data shown are representative of two 
experiments. 
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3.9. Detection of Tumor Cell Lysis 
Thus far, our data had shown TCL-6Dn inhibited proliferation of p883-pulsed 
tumor cells, but did not distinguish inhibition of tumor cell growth :from tumor cell 
lysis. Therefore, 51chromium release and JAM assays were performed to clarify 
whether TCL-6Dn lysed p883-pulsed tumor cells. 
3.9.1. Detection of Tumor Cell Lysis by 51Chromium Release Assays 
HLA-DR*0401+ tumor cell lines were labelled with 51 Cr, p883-pulsed and 
cultured with TCL-6Dn at effector to target ratios of 12:1, 6:1 and 3:1, which are 
similar to tumor cell and T cell ratios used in proliferation assays. The amount of 
51Cr-released :from target cells was measured after 5 h co-culture. As shown in Figure 
3.17, tumor cell lysis by TCL-6Dn was not above 2%. Additional assays were 
performed using higher effector:target ratios (50:1, 25:1 and 12.5:1) and lysis of 
p883-pulsed tumor cells by TCL-6Dn remained below 2% (data not shown). 
From these results we know that TCL-6Dn did not lyse p883-pulsed tumor 
cells within a 5 h co-culture period. We cannot conclude that TCL-6Dn was unable to 
lyse p883-pulsed tumor targets altogether, as TCL-6Dn may use a cytotoxic 
mechanism that requires a longer co-culture period. However, increasing the culture 
period for a 51Cr-release assay can cause inaccurate results due to increased 
background values or spontaneous 51Cr-release. Consequently, we also examined 
tumor cell lysis using the JAM assay, which allowed a longer co-culture period. 
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3.17. Detection of tumor cell lysis caused by TCL-6Dn using 51chromium release 
assays. 51Cr-labelled tumor cell targets were (A) un-pulsed or (B) p883-pulsed (1 
J.lg/ml) and co-cultured with TCL-6Dn for 5 h. The% 51Cr released from target cells 
was calculated as described in section 2.7.5.1. 
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3.9.2. Detection of Tumor cell Lysis by JAM Assays 
Tumor cell lysis was also measured using the JAM assay (Matzinger, 1991), 
which is based on DNA-fragmentation of the target cells. The fragmented DNA is 
washed through the glass fiber filter during cell harvesting using vacuum aspiration, 
while intact DNA in viable cells is trapped in the filter and reflects the amount of 
viable cells remaining. Tumor cells were labelled with 3H-thymidine for 18h, and 
initial amounts of 3H-thymidine incorporated into tumor cells was measured (see 
appendix 1). Thereafter, 3H-thymidine-labelled tumor cells were pulsed with p883 
and cultured with TCL-6Dn. Radioactivity remaining in the viable tumor cells was 
measured and used to calculate the percentage of tumor cell lysis. 
3.9.2.1. Lysis of Tumor Cells at 24, 48 and 72h 
Using the JAM assay we examined whether TCL-6Dn lysed p883-pulsed 
tumor cells and the approximate time required for lysis to occur. Therefore, TCL-6Dn 
was cultured with un-pulsed and p883-pulsed 3H-labelled tumor cell lines and the 
percent tumor cell lysis was calculated at 24, 48 and 72 h. As shown in Figure 3.18, 
TCL-6Dn did not lyse p883-pulsed T47D at 24 or 48h, while lysis increased to 31% 
at 72 h. Since T47D is an HLA-DR tumor cell line, the increased lysis at 72h may be 
due to bystander effect, as p883 activates TCL-6Dn to produce IFN-y, TNF-a and 
GM-CSF (see Section 3. 7.2). 
Lysis ofp883-pulsed T47D (I) and T47D-*0401 (I) occurred as early as 24 h, 
resulting in 55% and 72% tumor cell lysis, respectively. At 48 h the% lysis of these 
tumor cell lines increased, while after 72 h co-culture the % lysis remained constant. 
In the absence ofp883, lysis ofT47D (NI) and T47D-*0401 (NI) was less than 20% 
78 
(A) 
(B) 
(C) 
171 
.... 
100 
80 
171 60 s 
'$. 40 
20 
D Absence of p883 • Presence of p883 
Or-------~------~------~-------c 
100 
80 
60 
40 
20 
T47D y-T47D T47D*-0401 y-T47D-
Tf *0401 Tf 
O*-~==~~~==~~~==~~~==~ 
100 
80 
171 60 ]: 
'$. 40 
20 
T47D y-T47D T47D*-
0401 Tf 
y-T47D-
*0401 Tf 
0~------~------~------~----~ 
T47D y-T47D T47D-
*0401 
y-T47D-
*0401 
Figure 3.18. Detection of tumor cell lysis caused by TCL-6Dn at (A) 24h, (B) 48h 
and (C) 72h using JAM assays. Tumor cells were treated or not with IFN-y and 
labelled with 3H-thymidine. See Table 6.1 in Appendix 1 for the amount of 3H-
thymidine-incorporated into each cell line after 18 h. 3H-thymidine labelled tumor 
cells were cultured with TCL-6Dn in the absence (gray bars) or presence (black bars) 
of p883 (1 p.g/ml). Percent tumor cell lysis was calculated as described in section 
2.7.5.2. 
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at 24 h, 48 hand 72 h. Lysis ofun-pulsed T47D (I) and T47D-*0401 (I) increased up 
to 29% and 47% at 72 h, respectively. Notably, lysis of all IFN-y-induced tumor cell 
lines was higher compared to their non-induced counterparts. One plausible 
explanation is that IFN-y up-regulates molecules on the tumor cells, such as TNF 
receptors, making them more susceptible to lysis by TCL-6Dn. Alternatively, IFN-y 
treatment may pre-condition the tumor cells to undergo cell death. 
This time-course assay revealed that TCL-6Dn lysed p883-pulsed tumor cells 
after 24 h co-culture, which significantly increased at 48h, but remained stable at 72 h 
co-culture. Thus, the % tumor cell lysis was measured at 48 h for further JAM assays. 
3.9.2.2. Her-2 Specific Lysis of Tumor Cells 
To determine ifTCL-6Dn lysed tumor cells in a p883-specific manner, tumor 
cells were labelled with 3H-thymidine, pulsed with p883 or an irrelevent peptide and 
cultured with TCL-6Dn. The percentage of tumor cell lysis was measured after 48 h 
co-culture. As shown in Figure 3.19, TCL-6D lysed p883-pulsed, but not un-pulsed 
or irrelevant peptide-pulsed T47D and T47D-*0401 {NI and 1). 
Similarly, TCL-6D lysed p883-pulsed HT29 (I) and HT29-*0401 (NI and 1). 
Lysis of un-pulsed or irrelevant peptide-pulsed tumor cells may be due to recognition 
of the naturally processed p883 epitope, as IFN-y treatment of Her-2+ HT29 may 
induce natural processing and presentation of endogenous Her-2. 
MDA MB 435 and MDA MB 435-*0401 (NI and I) in the absence of peptide, 
presence of p883 or an irrelevant peptide was not lysed by TCL-6D. The percentage 
of tumor cell lysis was not higher than 20%, except when TCL-6D was cultured with 
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Figure 3.1 9. TCL-6Dn lysed tumor cells in a p883-specific manner. Tumor cc:Us Y.efe 
trented or ll()t with IFN--y and lobclled with lJ !-thymidine. Sec Table 6.2 in Appendix 
I for the amount of lH·tbymidinc inoorpornted into each cell line following 18 h. lH. 
thymidine-labelled tumor cells were eo-cultured with 1 C'L-6Dn in the abscn<:<: or 
peptide (blae~ ....._,),presence or p883 (I Jl8Jml: gray boiS) or an im:le>ant peptide (I 
Jlg/ml: blue boiS). Percent tumor cell lysis was calculated after 48h co-culture as 
described in section 2.7.5.2 
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p883-pulsed MDA MB 435 and MDA MB 435-*0401 the percentage of 
tumor cell lysis was 22% and 26%, respectively. 
In summary, tumor cell lysis occurred mainly when TCL-6Dn was co-cultured 
with p883-pulsed tumor cells. It was unclear from these data whether TCL-6Dn was 
activated by p883-presenting tumor cells or TCL-6Dn cells. However, lysis of the un-
pulsed or irrelevant peptide-pulsed Her-2 positive cell line HT29 suggested that TCL-
6Dn recognized the naturally processed p883 epitope generated by the tumor cell. 
Meanwhile, our results showed that TCL-6Dn recognized the p883 peptide causing 
tumor cell lysis, which led us to examine the exact mechanism used by TCL-6Dn to 
lyse tumor targets. 
3.10. Elucidating the Mechanism Used by TCL-6D to Lyse Tumor Cells 
3.10.1. Requirement for Tumor Cell and T Cell Contact 
Requirement for TCL-6Dn and tumor cell contact was assessed using both the 
JAM and tumor cell proliferation assays. HT29 and HT29-*0401 (NI and I) were 
labelled with 3H-thymidine and cultured in supernatant collected from un-stimulated, 
PHA-stimulated or p883-pulsed TCL-6Dn for 48h. In these assays, TCL-6Dn was 
stimulated for 48h in media without BFA present before the supernatants were 
collected and added to the 3H-labelled tumor cells, ensuring the cytokines were 
released into the supernatant. To confirm the T cells were stimulated to produce 
cytokines, TCL-6Dn was also cultured with PHA (5 J.Lg/ml) or p883 (1 J.Lg/ml) in 
media containing BFA. Intracellular cytokines analysis confirmed that TCL-6Dn 
produced IFN-y, TNF-a and GM-CSF (data not shown). Thus, supernatants collected 
from activated TCL-6Dn after 48 h should have also contained these cytokines. 
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As shown in Figure 3.20, tumor cell lysis may be mediated by a soluble factor 
produced by TCL-6Dn. Up to 54% of tumor cells cultured in supernatant collected 
from PHA-stimulated TCL-6Dn and up to 37% of tumor cells cultured in supernatant 
collected from p883-pulsed TCL-6Dn were lysed. Although tumor cell lysis in this 
assay was significantly lower than those attained when TCL-6Dn was co-cultured 
with tumor cells, these results indicated cell contact between TCL-6Dn and tumor 
cells was not essential for tumor cell lysis to occur. Since TCL-6Dn produced high 
levels of IFN-y, TNF-a, and GM-CSF, we suspect that tumor cell lysis may be 
cytokine-mediated. However, tumor cells cultured in various concentrations oflNF-
a. from 0.1 ng/ml to 100 ng/ml showed no difference in cell growth (data not shown). 
Therefore, the combination of IFN-y, TNF-a. or GM-CSF may be required for tumor 
cell lysis to occur. 
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Figure 3.20. Lysis of twnor cells cultured in supernatant collected from stimulated 
TCL-6Dn. 3H-thymidine-labelled twnor cells were cultured in supernatant collected 
from either un-stimulated (black bars), PHA-stimulated (5 J..Lg/ml; gray bars) or p883-
pulsed TCL-6Dn {lJ..Lg/ml; striped bars) for 48 h. See Table 6.3 in Appendix 1 for the 
amount of 3H-thymidine incorporated into each cell line following the 18 h labelling 
period. % lysis was calculated as cpm of twnor cell in T cell media - cpm of twnor 
cells in supernatant from TCL-6D I cpm of twnor cells in T cell media. Data shown 
are representative of two experiments. 
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To confirm that cell contact was not required for TCL-6Dn to lyse tumor cells, 
a transwell tumor cell proliferation assay was performed. Non-irradiated HT29-
*0401(1) was un-pulsed or pulsed with p883 and cultured with TCL-6Dn for 72 h. In 
addition, TCL-6Dn was cultured with tumor cells in the presence of a 0.4 J.llll 
membrane cell culture insert, which allowed peptide and soluble factors to freely pass 
though the membrane, but prevented tumor cell and T cell interaction. 
In the absence of TCL-6Dn, un-pulsed and p883-pulsed tumor cells showed 
strong proliferation in both the absence and presence of a cell culture insert (Figure 
3.21). In the presence ofTCL-6Dn, proliferation ofun-pulsed and p883-pulsed HT29-
*0401 (I) was significantly reduced in both the transwell and co-culture conditions. 
However, tumor cell proliferation was most drastically reduced in co-culture 
conditions. Although TCL-6Dn reduced proliferation of the un-pulsed tumor cells, 
these tumor cells were Her-2+ and IFN-y treated and possibly processing and 
presenting endogenous p883. Previously, in Figure 3.11, we showed that TCL-6Dn 
when co-cultured with p883-pulsed HT29-*0401 does not produce IFN-y. Therefore, 
TCL-6Dn may lyse the p883-pulsed tumor targets in a cytokine-independent manner. 
Altogether, these results suggested that TCL-6Dn was able to lyse tumor cells 
in the absence of cell contact, but for tumor cells to be completely inhibited by TCL-
6Dn cell both contact and p883 were required. In addition, these results indicate that 
TCL-6Dn used both a cytokine-dependent and independent mechanism to lyse p883-
pulsed tumor targets. 
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Figure 3.21. TCL-6Dn decreased the proliferation of Her2+ and p883-pulsed twnor 
cells in a contact-dependent and -independent manner. Untreated or IFN-y-treated, 
HT29-*0401 was un-pulsed or p883-pulsed (1 f.!g/ml) and cultured alone (black bars) 
or with TCL-6Dn (gray bars). Tumor cells and TCL-6Dn were either (A) separated by 
a transwell insert or (B) co-cultured for 72 h. Values represent the mean cpm and 
standard deviation of quadruplicate wells. Values above each bar represent the % 
inhibition and was calculated as described in section 2. 7 .6. 
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CHAPTER 4. DISCUSSION 
4.1. Summary of Findings 
Although TCL-6Dn proliferated in response to both HLA-DR~l *0401+and 
HLA-DR~l *0401- p883-pulsed DCs, we do not believe TCL-6Dn promiscuously 
responded to p883 presented by various HLA-DR alleles. Rather, it is probable that 
TCL-6Dn is auto-reactive to p883 presented by selfHLA-DR~l *0401 molecules. The 
high proliferation of TCL-6Dn in response to Ag-loaded DCs, but not Ag-loaded B 
cell lines, could be due to the presence of IL-12 or IL-10, depending on the APC 
present. TCL-6Dn may receive a survival signal, likely IL-12, from the DCs that it 
does not receive from other APCs. In tum, IL-12 may stimulate activated T cells to 
produce IL-2 and proliferate, independent of the HLA class II allele expressed on the 
DC. Meanwhile, engagement of CD40 on the B cell line and CD40L on the TCL-
6Dn, in the absence of antigen recognition, may cause B cells to produce IL-l 0, 
suppressing TCL-6Dn activation. 
TCL-6Dn lysed various tumor cells, in particular HT29-*0401+ cells, that 
were not loaded with exogenous p883. It is possible that Her-2 protein was shed from 
the tumor cell surface and processed by TCL-6Dn, resulting in auto-activation of the 
T cells. However, this is unlikely since TCL-6Dn lysed un-pulsed DR~ 1 *040 1 +, but 
not DR~ 1 *040 1-, Her-2+ tumor cell lines. Thus, the p883 epitope may be naturally 
processed and presented by HLA-DR~l *0401 molecules on the tumor cells. 
Although we have shown that TCL-6Dn lysed p883-loaded tumor targets, we 
have not determined the exact cytotoxic mechanism used by the T cell clone_ We 
know that activated TCL-6Dn secreted IFN-y and TNF-a and we believe that the anti-
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tumor cytotoxic effect of TCL-6Dn is partly due to a synergistic affect of both 
cytokines. Tumor cell lysis was mediated by a soluble factor produced by TCL-6Dn, 
but cell contact increased lysis. Therefore, TCL-6Dn possibly lysed tumor target cells 
via multiple mechanisms that were both contact-dependent and independent. 
4.2. HLA-DR Restriction offCL-6Dn 
Various antigen-derived epitopes that promiscuously bind to multiple HLA-
DR and HLA-DP molecules exist (Neumann et al., 2004A, Neumann et al., 2004B, 
Mandie et al., 2005, Kobayashi et al., 2005). In particular, Her-2 p883 was shown to 
be presented by HLA-DRl, -DR4, -DR52 and -DR53 (Kobayashi et al., 2000). 
Southwood et al. (1998), suggested a motif for promiscuous binding peptides that is 
characterized by a large aromatic or hydrophobic residue at position one (P1) and a 
small non-charged residue at position 6 (P6). Her-2 p883 fills this criterion as it 
possesses tryptophan and phenylalanine, either of which could be a potential 
candidate for P1 and serine or isoleucine that could fit at P6. As such, the synthetic 
Her-2 p883 peptide may promiscuously bind to various HLA-DR molecules. 
TCL-6D responded equally well to p883 presented by HLA-DRP1 *0401+ 
PBMCs and DR-transfected L cells (Kobayashi et al., 2000). This T cell clone was 
believed to be restricted by the DRP1 *0401 molecule based on its proliferation in 
response to the L cell transfectant. Kobayashi et al. (2000) did not report whether 
TCL-6D proliferated in response to a non-DRP1 *0401 APC. However, the T cell line 
that we expanded responded to p883 presented by mature DCs from 
DRP1*0401,07;DR53 and DRP1*1501,1301; DR5l,DR52 donors. Despite the high 
degree of specificity of ligand recognition by TCRs (Reviewed in McFarland & 
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Beeson, 2002), antigen-specific T cells have been known to respond to peptide 
presented by various HLA-DR molecules (Doherty et al., 1998, Hemmer et al., 2000, 
Sotiriadou et al., 2001). Hypervariable regions of the HLA class II molecule 
encompassing residues 67-71, in particular residue 71, and residue 86 have been 
known to affect peptide binding and recognition by the TCR (Demotz et al., 1993, 
McKinney et al., 1994). As shown in Table 4.1, both DRP1 *0401 and DR52 alleles 
possess amino acids lysine and glycine at positions 71 and 86, respectively, while 
DR51 and DRP1 *0701 posses amino acids arginine and glycine at positions 71 and 
86, respectively. Therefore, overlapping amino acid sequences at these positions may 
allow TCL-6Dn to recognize p883 presented by various HLA class II molecules. We 
have not presented evidence to show that TCL-6Dn responds to p883 presented by 
HLA-DR52. Therefore, we should have addressed this issue by testing the 
proliferative response of TCL-6Dn to p883-pulsed DCs from DRP 1 *040 1 +, DR52-, 
DRPl *0401-, DR52- and DRPl *0401+, DR52+ individuals. 
Altogether, we do not believe that TCL-6Dn promiscuously responded to p883 
presented by multiple HLA-DR alleles. An alternative, and more plausible, 
explanation is that TCL-6Dn is auto-reactive to p883 presented by selfHLA-P1 *0401 
molecules. TCL-6Dn did not proliferate when cultured with peptide in the absence of 
DCs as TCL-6Dn may receive a survival signal, likely IL-12, from the DCs that it 
does not receive from other TCL-6Dn cells. In accordance, other studies have shown 
that IL-12 acts on activated Th cells resulting in T cell proliferation and increased 
cytokine production (Dredge et al., 2002, Knutson & Disis, 2004) 
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Table 4.1. Amino acid sequence ofHLA-DR molecules at positions 67 to 71 and 
position 86. 
HLA-DR Allele 
DR~1*0401 
DR~1*0402 
DR~1*0701 
DR~1 *1301 
DR~1 *1501 
DR~5 (DR51) 
DR~3 (DR52) 
DR~4 (DR53) 
Position 67-71 
Amino Acids** 
LLEQK 
ILEDE 
ILEDR 
ILEDE 
ILEQA 
FLEDR 
LLEQK 
LLERR 
Position 86 
Amino Acid** 
G 
v 
G 
v 
v 
G 
G 
v 
**Major Histocompatibility Complex Data Base www.ncbi.nlm.nih.gov/mhc 
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4.3. Differential Response ofTCL-6Dn to Various p883-Presenting APCs 
Interaction between the TCR and peptide:HLA complexes, without a second 
co-stimulatory signal, is sufficient to activate memory and effector T cells (London et 
al., 2000). Consequently, we expected TCL-6Dn to be activated by all APCs 
presenting p883 in the context of HLA-DR~1 *0401, yet TCL-6Dn responded 
differently to the various p883-loaded APCs. 
TCL-6Dn proliferated strongly to antigen when DCs were used as APCs. This 
result was expected as DCs are considered professional APCs. Upon antigen 
presentation to TCL-6Dn, CD40 on the DC may bind with CD40L on the T cell. 
Ligation of CD40/CD40L up-regulates HLA class II and co-stimulatory molecules, 
such as CD80 and CD86, improving the ability of DCs to present antigen and activate 
T cells (Caux et al., 1994). CD40/CD40L ligation also triggers DCs to produce 
cytokines such as IL-8, IL-12, TNF-a and IL-18 (Caux et al., 1994, Cella et al., 1996, 
Koch et al., 1996, Gardella et al., 1999). IL-12 has been shown to augment the 
proliferation and cytokine production of antigen-specific Th cells (Trinchieri et al., 
1994, Cella et al., 1996, Knutson & Disis, 2004). Therefore, DCs may provide a co-
stimulatory signal and generate IL-12, resulting in higher proliferation of TCL-6Dn. 
An alternative explanation is that TCL-6Dn may be activated indirectly by the DCs as 
p883-activated TCL-6Dn generated TNF-a, which is known to trigger DC maturation 
and IL-12 production (Sallusto et al., 1995, Morrison et al., 2003). 
A major counter argument that TCL-6Dn required co-stimulation, is that B 
cell lines also express high amounts of CD40, CD80 and CD86, yet TCL-6Dn failed 
to proliferate when B cell lines were used as APCs. In addition, Kobayashi et al. 
(2000) showed that TCL-6D did not require co-stimulation for activation, as the CD4+ 
91 
T cell clone responded equally well to antigen presented by PBMCs and DR-
transfected L cells. Although the B cell lines used in this study expressed the relevant 
co-stimulatory molecules, these B cell lines were EBV -transformed and likely 
produced IL-l 0, which may suppress TCL-6Dn activation. Engagement of CD40 on 
the B cell and CD40L on the T cell may cause B cells to produce higher amounts of 
IL-10, suppressing TCL-6Dn activation. In fact, Duddy et al. (2004) have shown that 
engagement of CD40 on the B cell with CD40L on the T cell, in the absence of Ag 
recognition, increases the amount ofiL-10 generated by the B cell. 
The differences in TCL-6Dn activation observed with antigen-loaded B cells 
and L cells may be due to the number of p883:HLA complexes present on the APC. 
Although B cell lines expressed higher amounts ofHLA-DR, these class II molecules 
may be tightly bound to self peptides that can not be easily displaced to allow loading 
of exogenous p883. Thus, L cells may possess a higher number of p883:HLA 
complexes. However, a more plausible explanation is that B cells, but not L cells, 
generate IL-10 which may suppress activation ofTCL-6Dn. 
In summary, it is most likely that TCL-6Dn proliferated strongly in response 
to p883-pulsed DCs because TCL-6Dn received a survival signal, possibly IL-12, 
which was absent when TCL-6Dn was cultured with other APCs. Indeed, the poor 
response to p883-pulsed B cell lines may be due to the production of IL-l 0, which 
may suppress TCL-6Dn activation. We cannot conclude that TCL-6Dn proliferation is 
dependent on the presence of IL-12, yet this could be addressed by measuring TCL-
6Dn proliferation in the presence ofiL-12 alone, IL-12 and IL-10 or IL-10 alone. 
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4.4. Tumor Cell Lysis 
Since TCL-6Dn was activated by p883-loaded DCs, PBMCs and DR-
transfected L cells, we expected that p883-loaded HLA-DR+ tumor cells would also 
activate TCL-6Dn. In contrast, TCL-6Dn appeared to be cytotoxic toward Ag-loaded 
tumor cell lines. Anti-tumor cytotoxic CD4+ T have also been described by others 
(Chen & Hersey, 1992, Takahashi et al., 1995, Thomas & Hersey, 1998a, Manici et 
al., 1999, Schultz et al., 2000). In particular, one CD4+ T cell proliferated in response 
to Ag-loaded PBMCs, while the T cell was cytotoxic toward Ag-presenting DR+ 
tumor cells (Manici et al., 1999). 
The Ag dose used to stimulate in vitro-generated T cells is an important factor 
in determining their phenotype and function (Ise et al., 2002). High doses of Ag and 
repetitive stimulation ofT cells in vitro can induce cytotoxic properties (Janssens et 
al., 2003). Possibly, TCL-6Dn possessed cytotoxic properties due to high dose antigen 
stimulation of the naive CD4+ T cells, cloned by Kobayashi et al. (2000). Meanwhile, 
the cytotoxic properties of TCL-6Dn may have increased with further clonal 
expansions of the T cell clone. 
JAM assays performed using adherent 3H-thymidine-labelled target cells could 
lead to falsely high killing values due incomplete harvesting of the adherent 
radioactive-labelled cells. Although, we do not think this occurred in our assays as we 
collected all adherent radioactive-labelled target cells by adding trypsin to all wells 
and three rounds of washing were performed during cell harvesting. Others have 
shown that at least three rounds of washing is required during cell harvesting to 
effectively transfer all radioactive DNA from adherent cells onto the filter mat (Bohm 
et al., 1998, Atarashi et al., 2000). 
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Despite limitations of the JAM assay, it was useful in distinguishing tumor 
cell lysis from inhibition of cell growth. TCL-6Dn lysed the 3H-labelled tumor cell 
targets, as tumor cells underwent DNA-fragmentation, which is characteristic of the 
early stages of cell death, but not growth inhibition (Weis et al., 1995). Yet, we did 
not perform electrophoresis to confirm that DNA fragmentation occurred in the 3H-
labelled target cells. We cannot exclude the possibility that 3H-thymidine labelling 
enhanced tumor cell death, but tumor cell lysis was significantly higher when tumor 
cells were p883-loaded and cultured with TCL-6Dn compared to tumor cells cultured 
alone. 
4.4.1. Cytotoxic Response ofTCL-6Dn toward various p883-pulsed HLA-
DR+ Tumor Cell Lines 
TCL-6Dn lysis of p883-pulsed HLA-DR expressing breast and colon cancer 
cell lines (T47D and HT29, respectively), but not p883-loaded breast cancer cell line 
(MDA MB 435) shown in figure 3.19 is difficult to explain. Our data in figure 3.9 
showed that growth ofp883-pulsed MDA MB 435 cells was significantly inhibited by 
TCL-6Dn, while figure 3.19 showed that TCL-6Dn did not lyse peptide-pulsed MDA 
MB 435 cells. On the contrary, our data has shown that TCL-6Dn can lyse and inhibit 
growth of both cell lines T47D and HT29. 
Potentially, IFN-y produced by TCL-6Dn may inhibit MDA MB 435 cell 
growth, as IFN-y can arrest the cell cycle at the Go/01 stage (Garbe & Krasagakis, 
1993, Kortylewski et al., 2004). Our data showed that IFN-y-treatment, used to induce 
HLA class II expression, decreased tumor cell proliferation. This was slightly evident 
with T47D and HT29 cell lines, but IFN-y drastically affected the proliferation of 
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MDA MB 435. This supports our hypothesis that IFN-y produced by p883-pulsed 
TCL-6Dn could inhibit the proliferation of the tumor cell lines, particularly MDA MB 
435. However, lysis of MDA MB 435 cells may have been undetected as non-
proliferating MDA MB 435 cells would not incorporate the 3H-thymidine used in the 
JAM assay. 
On the contrary, MDA MB 435 may not be susceptible to the death-inducing 
mechanism used by TCL-6Dn to lyse T47D and HT29. Although we have referred to 
MDA MB 435 as a breast cancer cell line, Ross et al. (2000) showed that MDA MB 
435 cells express melanoma associated genes. Therefore, MDA MB 435 may be a 
melanoma cell line. Other researchers have shown that some melanoma cells are 
resistant to killing by FasL and TNF-a, but susceptible to TRAIL-induced killing 
mediated by CD4+ T cells (Thomas & Hersey, 1998a, Thomas & Hersey, 1998b ). It is 
not clear why melanoma cells would be resistant to TNF-a and FasL, but susceptible 
to TRAIL, as the receptors for these ligands belong to the TNF family and their 
mechanism of inducing cell death is thought to be similar (Reviewed in Baker & 
Reddy, 1998, Ozoren & El-Deiry, 2003). Perhaps, MDA MB 435 may not express, or 
express a mutated form, of the receptors for the death-inducing ligand used by TCL-
6Dn. Similarly, Pan et al. (1997) showed that TRAIL-resistant tumor cells expressed 
TRAIL receptors that lacked the intracellular domain. 
4.4.2. Increased Lysis of IFN-y Treated Tumor Cell Lines 
IFN-y is a well known modulator of HLA class II expression on tumor cells 
in-vitro, and in-vivo (Chang & Flavell, 1995, Muczynski et al., 1998, Walter et al., 
2000, Boss & Jensen, 2003, Propper et al., 2003, Zehbe et al., 2005). Since we tested 
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whether HLA class lt tumor cells processed and presented epitopes generated from 
endogenous Her-2 protein, tumor cells were pre-treated with rhiFN-r to up-regulate 
class II expression. We detected higher killing of peptide-loaded tumor cells that were 
pre-treated with IFN-r compared to their un-treated counterparts. One explanation for 
these results is that IFN-r up-regulated the expression of HLA class II and class II 
accessory molecules in the tumor cells. As a result, IFN-y-treated tumor cell lines may 
process endogenous Her-2 protein and present the naturally processed Her-2 883-899 
epitope, increasing the number of peptide:HLA class II complexes recognized by 
TCL-6Dn. Indeed, studies have shown that an increase in the number of peptide:class 
II complexes can enhance T cell activation (Cochran et al., 2000, Reay et al., 2000). 
However, this explanation is unlikely as TCL-6Dn lysed HLA-DR+ and HLA-DK 
tumor cell lines. 
A more probable explanation is that IFN-y treatment of the tumor cells, prior 
to co-culture with TCL-6Dn, up-regulated cell death receptors on tumor cells. IFN-r 
has been shown to increase expression of several apoptotic-related molecules 
including death receptors, such as members of the Bcl-2 family or caspases (Ruiz-
Ruiz et al., 2000, Fulda & Debatin, 2002, Ossina et al., 1997, Ugurel et al., 1999). As 
a consequence, tumor cell lines in this study may be highly susceptible to apoptosis 
due to IFN-r modulation of apoptotic-related proteins. 
4.5. Mechanisms Potentially Responsible for Tumor Cell Lysis 
Our data suggested that TCL-6Dn lysed tumor cells via multiple pathways that 
were both contact-dependent and -independent. This was evident as tumor cells were 
lysed when cultured with TCL-6Dn in the presence of a transwell insert, preventing 
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contact between the tumor cell and T cells. As well, tumor cells were lysed when 
cultured in supernatant collected from stimulated TCL-6Dn. However, tumor cell 
lysis was higher when tumor cells were co-cultured with TCL-6Dn. The increased 
tumor cell lysis observed in the co-culture conditions could be due to the tumor cell 
being in closer proximity to the CD4+ T cells secreting cytokines and not a result of 
cell to cell contact. Alternatively, cytokines present in the supernatant collected from 
stimulated TCL-6Dn may lose their efficiency after collection, resulting in lower 
tumor cell lysis. Meanwhile, we believe that TCL-6Dn lysed target cells via multiple 
mechanisms that were contact-dependent and independent. 
Several cytotoxic Th1 cells that utilize the perforin/granzyme pathway to kill 
melanoma, lung cancer, T lymphoma and leukemia cells have been described 
(Thomas & Heresy, 1998a, Semino et al., 1999, Echchakir et al., 2000, Porakishvili et 
al., 2004). Upon recognition of HLA:peptide complexes by the TCR, perforin 
molecules, stored in cytoplasmic granules within the cytotoxic T cell, are released and 
form holes in the target cell membrane (Liu et al., 1995). Thereafter, target cell death 
occurs via a granzyme-mediated mechanism (Heusel et al., 1994). It is unlikely that 
tumor cell lysis in our study was perforin/granzyme-mediated, as this mechanism of 
cell killing is contact-dependent and a fast process (Liu et al., 1995). Meanwhile, our 
data showed that tumor cells were not lysed at 5 h, but were susceptible to lysis at 24 
h, which is characteristic of Fas/FasL and cytokine-mediated cell killing (Stalder et 
al., 1994, Breu-Martin et al., 1995). However, to confirm TCL-6Dn did not kill via 
the perforin/granzyme pathway we should have examined granzyme expression in 
TCL-6Dn. 
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The primary cytotoxic mechanism used by CD4+ T cells is believed to be 
Fas/FasL (Stalder et al., 1994). Therefore, we investigated whether TCL-6Dn killed 
tumor cells via Fas/FasL interactions. The interaction between FasL on the T cell and 
its receptor, Fas, on the target cell induces target cell death via the death domain-
mediated recruitment of caspases (Reviewed in Ozoren & El-Deiry, 2003). All tumor 
cell lines used in our study expressed Fas (also known as CD95 or AP01; data not 
shown), which corresponds with other published studies (Thomas & Hersey, 1998a, 
Houston et al., 2003). In addition, Fas ligand (also known as FasL, AP01-L or 
CD95L) was expressed on TCL-6Dn (data not shown). 
The requirement for cell to cell contact in Fas-induced killing is controversial. 
Ligation between Fas and FasL is required to initiate the death signal, yet a 26-kDa 
soluble and functional form of FasL can be released from activated T cells by 
metalloproteinases (Kayagaki et al., 1995, Tanaka et al., 1995). Conversely, Tanaka et 
al. (1998) demonstrated that the soluble form ofFasL failed to initiate target cell lysis. 
If TCL-6Dn lysed tumor cells via the Fas/FasL pathway, mediated by soluble FasL, 
one would expect TCL-6Dn to lyse all Fas + tumor cells, regardless of p883 being 
present. Rather, our results showed that TCL-6Dn lysed p883-pulsed, but not all un-
pulsed, Fas + targets. Meanwhile, we did not observe a correlation between Fas 
expression on the tumor cells and tumor cell lysis. In addition, TCL-6Dn failed to lyse 
the p883-pulsed B cell lines, which were also shown to express Fas molecules (data 
not shown). As a result, we do not believe TCL-6Dn lysed tumor targets via the 
Fas/FasL pathway. 
Other studies have shown that CD4+ T cells utilize cytokine-mediated 
mechanisms, such as IFN-y and TNF-a, to lyse tumor cells (Mumberg et al., 1999, 
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Brady et al., 2000, Lindencrona et al., 2004). IFN-y is characteristic of a Thl response 
to tumors (Billiau et al., 1998) and is a multi-functional cytokine with 
immunomodulatory and anti-proliferative effects. The cytotoxic effect of IFN-y may 
be direct (Willamson et al., 1983, Novelli et al., 1994) or indirect, as IFN-y can up-
regulate the expression of cell death receptors, such as Fas, TNF-a receptors (TNF-R) 
and TNF-related apoptosis-inducing ligand (TRAIL) (Ruggiero et al., 1986, Itoh et 
al., 1991, Sedger et al., 1999, van Geelan et al., 2003, Felli et al., 2005). However, we 
do not believe that IFN-y produced by TCL-6Dn was solely responsible for tumor cell 
lysis because tumor cells were not lysed by IFN-y treatment used to up-regulate HLA-
DR expression. 
We believe the anti-tumor cytotoxic effect of TCL-6Dn was due to a 
synergistic affect of IFN-y and TNF-a as tumor cells were cultured in various 
concentrations of rhTNF-a and cell lysis was undetected (data not shown). The 
cytotoxic effect ofTNF-a occurs as TNF-a binds to its receptor, TNF-R, on the target 
cell surface. Upon ligand binding, downstream signals are transmitted that lead to 
activation of caspases and pro-apoptotic signals, resulting in target cell death 
(Reviewed in Baker & Reddy, 1998). IFN-y and TNF-a have also been shown to 
cause cells to arrest in the G0/G1 phase of the cell cycle, resulting in inhibition of cell 
growth (Pusztai et al., 1993, Hillman et al., 1994). 
Another study has shown that peptide-specific CD4+ T cells kill peptide-
presenting melanoma cells in-vitro using a contact-independent mechanism, which 
they suggested was cytokine-mediated (Brady et al., 2000). Their data also showed 
that melanoma cell lysis was not prevented with an anti-IFN-y mAb, suggesting that 
other factors were involved. Other studies have shown that alone TNF-a and IFN-y 
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cause minimal killing of tumor cell lines, while a combination of both cytokines 
increases killing (Willamson et al., 1983, Deem et al., 1991, Breu-Martin et al., 1995, 
Manos & Jones., 2001). Subsequent experiments performed in Dr. Drover's 
laboratory have shown that anti-IFN-y can inhibit tumor cell lysis by p883-pulsed 
TCL-6Dn, while anti IFN-y and anti TNF-a have a synergistic effect. The ability of 
IFN-y to up-regulate a variety of cellular receptors, including TNF-R, suggests one 
mechanism responsible for the synergism between these two cytokines (Ruggiero et 
al., 1986, Itoh et al., 1991). 
4.6. Natural Processing of the Her-2 Protein by Tumor Cell Lines 
Natural processing and presentation of the endogenous Her-2 protein by tumor 
cells was evaluated by measuring TCL-6Dn recognition of un-pulsed HLA-DR+ and 
Her-2+ tumor cells. Other studies have shown that tumor cells can naturally process 
and present epitopes generated from various tumor antigens (Brady et al., 2000, 
Schultz et al., 2000, Kobayashi et al., 2005). Perez et al. (2002) demonstrated that 
Her-2+ and class Ir colon, pancreatic and breast cancer cells were capable of 
processing and presenting a Her-2-derived class II epitope. Similarly, our results 
suggested that some Her-2+ and HLA class Ir tumor cells were capable of processing 
and presenting the 883-899 epitope for CD4+ T cell recognition. 
TCL-6Dn lysed various tumor cells, in particular HT29-*0401+ cells, that 
were not loaded with exogenous p883. It is possible that Her-2 protein was shed from 
the tumor cell surface and processed by TCL-6Dn resulting in auto-activation of the T 
cells. However, TCL-6Dn lysed un-pulsed DRP1 *0401+, but not DRP1 *0401-, Her-2+ 
tumor cell lines. Thus, the p883 epitope may be naturally processed and presented by 
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HLA-DR~1 *0401 molecules on the tumor cells. These results correspond with data 
published by Perez et al. (2002) who also showed that HT29 tumor cells could 
process and present a Her-2-derived HLA class II epitope that differed from the p883-
899 epitope by one amino acid. However, Perez et al. (2002) did not report whether 
they used other Her-2+ cell lines, such as T47D. 
The inability of TCL-6Dn to recognize the Her-2+ tumor cell line T47D does 
not indicate this tumor cell line is unable to process endogenous tumor antigens. It is 
possible that HT29, but not T47D, possess the appropriate antigen processing 
molecules required to process and present Her-2-derived epitopes for class II 
presentation. Yet, T47D may process the Her-2 protein, but not generate the p883 
epitope to activate TCL-6Dn. Alternatively, Her-2 expression on T47D may be 
modulated by pre-treatment with IFN-y or IFN-y generated by the activated TCL-
6Dn. IFN-y can effect the expression of several proto-oncogenes (Beatty & Paterson, 
2000, Brouwers et al., 2003, Li et al., 2003, Reddy et al., 2003). In particular, IFN-y 
can suppress Her-2 expression in human ovarian and prostate cancer cells (Marth et 
al., 1990, Marth et al., 1992, Fady et al., 1992, Kominsky et al., 2000). Therefore, 
IFN-y may modulate Her-2 expression on some ofthe Her-2+ tumor cell lines used in 
this study. 
We cannot exclude the possibility that Her-2 may be shed from the tumor cell 
surface, processed and presented by HLA-DR~1 *0401 molecules on the CD4+ T cell 
clone, resulting in self-activation. However, this explanation does not address why 
TCL-6Dn would only recognize the HLA-DR~1 *0401+, Her-2+ tumor cells. This 
explanation also implies that HT29, but not T47D, is able to shed the Her-2 protein. 
Recent proliferation assays conducted in Dr. Drover's laboratory showed that TCL-
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6Dn failed to proliferate when cultured in supernatant collected from the Her-2+ 
breast tumor cell line, SKBR3, which is thought to shed the Her-2 protein. As a result, 
we believe that tumor cells may be able to process the endogenous Her-2 protein. 
4.7. Potential Implications of Findings 
TCL-6Dn responded differently to p883 presented by various APCs. Whether 
TCL-6Dn recognized differences in the antigen-presenting cell and adjusted their 
cytokine production accordingly is unknown. In this study, we showed that TCL-6D 
produced IFN-y when p883-pulsed tumor cell lines and B cell lines were used as 
APCs. However, we did not address whether TCL-6Dn produced additional 
cytokines in response to Ag-pulsed tumor cells. It would be interesting to discern 
whether TCL-6Dn generates a different cytokine profile when it recognizes Ag-
pulsed tumor cells than in response to Ag-loaded DCs. We believe that TCL-6Dn 
may have produced IL-2 in response to Ag-loaded DCs, but not Ag-loaded tumor 
cells. This experiment could explain why TCL-6Dn proliferated in response to Ag-
loaded DCs, but not other APCs. 
There are examples of CD4+ T cells that lyse HLA class It tumor cells, yet 
most tumor cells are constitutively HLA class II negative. However, CD4+ T cells 
that secrete cytokines upon activation can potentially up-regulate class II expression 
on tumor cells or initiate tumor cell lysis by cytokine-mediated mechanisms. This is 
why we set out to examine the exact mechanism used by TCL-6Dn to lyse the Ag-
loaded tumor cells. Whether TCL-6Dn used a cytokine- or Pas-mediated mechanism 
could be determined with blocking mAbs specific for Fas, IFN-r and TNF-a. 
Although data from Dr. Drover's laboratory (data not shown) determined that 
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blocking the interaction between IFN-y and TNF-a and their appropriate receptors 
decreased killing of the Ag-loaded tumor cells, tumor cell lysis was not completely 
abrogated. This could be due to insufficient blocking of the IFN-y and TNF-a or 
TCL-6Dn may utilize additional mechanisms to lyse the antigen-loaded tumor cells. 
Apart from our in-vitro fmdings, the presence of Her-2-specific cytotoxic 
CD4+ T cells among the infiltrating T cells in Her-2 positive carcinoma in-vivo 
remains undetermined. Potentially, this could be investigated using HLA-class II 
tetramers carrying the Her-2 883-899 peptide in the context of relevant HLA-DR 
molecules, such as HLA-DR~1 *0401, in DR4+ cancer patients. Therefore, binding of 
the tetramer could identify p883-specific infiltrating CD4+ T cells from Her-2+ and 
HLA-DR~ 1 *040 1 + carcinomas. However, even if tumor cells are capable of antigen 
presentation in vivo, the precise location of Ag-presentation may remain unclear. 
Tumor antigen presentation may occur at the tumor site as approximately 52% of 
tumors contain moderate to large numbers of infiltrating T cells (Oldford et al., 2004). 
Alternatively, antigen presentation could occur at the regional lymph node as tumor 
cells migrate to the lymph node (Leong et al., 2006, Al-Batran et al., 2005, Yang et 
al., 1997). It is unlikely that naive CD4+ T cells with an appropriate TCR would be 
exposed to Ag at the tumor site or that tumor cells lacking co-stimulatory molecules 
could activate naive CD4+ T cells. However, tumor antigens that are shed may be 
picked up and processed by intratumoral professional APCs. This could induce HLA 
class II expression on tumor cells through the release of cytokines and enable the 
tumor cell to present tumor-antigen derived peptides. Alternatively, tumor cells can 
metastasize via the lymphatic circulation, draining into the lymph whereby Ag-
presentation by the tumor cell could occur. 
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Her-2 epitope 883 to 899 may be a naturally processed epitope expressed on 
the surface of some tumor cells. This is consistent with results published by Perez et 
al (2002) who showed natural processing and presentation of a similar Her-2 epitope 
by tumor cell lines. Although Kobayashi et al. (2000) showed the Her-2 p883-899 
epitope is naturally processed by professional APCs, this does not imply the whole 
Her-2 protein is processed via the endocytic pathway. Other studies have shown this 
occurrence with MAGE-A3 tumor antigen as epitopes 281- 295 and 247-258 were 
presented by MAGE-A3+ tumor cells to CD4+ T cells, whereas epitopes 114-127 and 
121-134 were not expressed on the surface ofMAGE-A3+ tumor cells (Chaux et al., 
1999, Manici et al., 1999). Therefore, it would be interesting to determine if the whole 
Her-2 protein is processed by identifying additional Her-2-derived antigenic peptides 
that are presented on the surface ofHer-2+ tumor cells. 
While HLA class II molecules generally present peptides from exogenous 
proteins, cytosolic antigen-derived peptides have been eluted from class II molecules 
(Reviewed in Zhou & Blum, 2004). Where antigen processing and loading ofpeptides 
derived from cytosolic proteins occurs is unclear. Studies have shown that cytosolic 
proteins, such as GAD and influenza viral proteins require proteasomal and 
endosomal compartments of the Class I antigen processing for the presentation of 
class II epitopes (Lich et al, 2000, Tewari et al., 2005, Dorfel et al., 2005). Other 
studies have shown that cytosolic proteins, such as the EBV nuclear proteins and the 
NeoR antigen, are processed by acidic proteases in the lysosomal compartments of the 
class II processing pathway (Nimmetjahn et al., 2003, Paludan et al., 2005). Whether 
the Her-2 protein is processed via the class I or class II antigen processing pathway 
and loaded onto HLA class II molecules remains undetermined. 
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Since Her-2 is expressed at low levels in normal cells, high-affinity CD4+ T 
cells specific for Her-2-derived epitopes may be rendered tolerant or deleted 
(Reviewed in Sprent, 2001). The presence of Her-2 on normal cells could trigger an 
autoimmune response if high affinity CD4+ T cells reacted with APCs presenting low 
levels of Her-2-derived peptides. However, it is possible that epitopes expressed on 
normal cells are below the threshold level for T cell recognition, while over-
expression in tumor cells can initiate a Her-2 specific T cell response. Whether 
antigen-presenting tumor cells would generate low-, intermediate- or high-affinity 
CD4+ T cells in vivo is undetermined. Low affinity T cells may be inefficient in 
providing tumor protection in vivo, whereas high affinity T cells could trigger an 
autoimmune response (Zeh et al., 1999). However, if tumor antigens are processed in 
non-endocytic compartments, tumor cells could present different tumor peptides than 
professional APCs. Therefore, tumor cells could stimulate a different repertoire of 
CD4+ T cells that may not initiate an auto-immune response. 
In conclusion, we have demonstrated that Her-2 p883-specific CD4+ T cells 
recognize some Her-2+ and HLA class Ir tumor cell lines, indicating this epitope 
may be expressed on the surface of tumor cells. Since various Her-2 epitopes 
recognized by CD8+ T cells have been discovered (Fisk et al., 1995, Rongcun et al., 
1999, Baxevanis et al., 2002, Sotiropoulou et al., 2003), incorporation of the Her-2 
p883 epitope with class !-restricted epitopes in vaccines could result in a more 
efficient and longer lasting anti-tumor immune response. This CD4+ T cell clone 
may also be of importance for immunotherapeutic strategies that utilize antigen-
specific T cells, as TCL-6Dn was activated to proliferate and generate cytokines 
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when Ag-loaded DCs were used as APCs, but TCL-6Dn was cytotoxic toward Ag-
loaded tumor cells. 
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Table 6.1. The Amount of 3H-thymidine incorporated by 1 x 104 cells of non-induced 
and IFN-y-induced tumor cell lines (shown in Figure 3.18) following 18 h labelling 
with 5 J.t.Cilml oftritiated-thymidine (6.7 Ci/mmol). 
Cell Line cpm values obtained for 1x104 cells of each cell line 
Non-induced IFN-y-induced 
T47D 6253 2643 
T47D-*0401 5301 5499 
Table 6.2. The Amount of 3H-thymidine incorporated by 1 x 104 cells of non-induced 
and IFN-y-induced tumor cell lines (shown in Figure 3.19) following 18 h labelling 
with 5 J.t.Ci/ml of tritiated-thymidine ( 6. 7 Ci/mmol). 
Cell Line cpm values obtained for 1x104 cells of each cell line 
Non-induced IFN-y-induced 
T47D 9418 7094 
T47D-*0401 5494 4294 
HT29 2490 4536 
HT29-*0401 6954 2432 
MDAMB435 5528 1069 
MDA MB 435-*0401 5041 895 
Table 6.3. The Amount of 3H-thymidine incorporated by 1 x 104 cells of non-induced 
and IFN-y-induced tumor cell lines (shown in Figure 3.20) following 18 h labelling 
with 5 J.LCilml oftritiated-thymidine (6.7 Ci/mmol). 
Cell Line cpm values obtained for 1x104 cells of each cell line 
Non-induced IFN-y-induced 
HT29 2490 4536 
HT29-*0401 6954 2432 
Table 6.4. The spontaneous and maximum release of 51Cr from the 51Cr-labelled 
tumorce nr h ·p- 317 mess ownm 1gure 
Tumor Cell Un-pulsed p883-pulsed 
Line 
Spontaneous Maximum Spontaneous Maximum 
Release Release Release Release 
T47D 606.1 4859.9 694.1 4684.2 
T47D*0401 1281.3 6194.6 1164.9 6165.0 
HT29 708.6 6807.0 651.1 6589.2 
HT29*0401 455.6 1925.5 462.6 1858.8 
134 
135 




